{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Purpose\n",
    "\n",
    "The purpose of this script is to read in pdf protocol files"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Import NLTK packages"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [],
   "source": [
    "# import nltk\n",
    "\n",
    "from nltk.tokenize import word_tokenize\n",
    "from nltk.corpus import stopwords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "showing info https://raw.githubusercontent.com/nltk/nltk_data/gh-pages/index.xml\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#nltk downloader to chose packages\n",
    "nltk.download()  "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###  Attempt with pdfminer\n",
    "\n",
    "__Code below is based on pdfmider six__\n",
    "> https://github.com/pdfminer/pdfminer.six\n",
    "\n",
    "> https://pdfix.net/pdfix-sdk-for-python-has-just-been-released/\n",
    "\n",
    "\n",
    "__Additional pdfminder github page__\n",
    "\n",
    "> https://github.com/euske/pdfminer\n",
    "\n",
    "\n",
    "__For code below, there are some errors section headings.__\n",
    "\n",
    "Research these wrappers as possible solution:\n",
    "\n",
    "Slate (wrapper for pdfminer): \n",
    "https://github.com/timClicks/slate\n",
    "\n",
    "PDFquery (wrapper for pdfminer): \n",
    "https://github.com/jcushman/pdfquery"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "from pdfminer.pdfinterp import PDFResourceManager, PDFPageInterpreter\n",
    "from pdfminer.pdfpage import PDFPage\n",
    "from pdfminer.converter import XMLConverter, HTMLConverter, TextConverter\n",
    "from pdfminer.layout import LAParams\n",
    "import io\n",
    "\n",
    "def pdfparser(data):\n",
    "\n",
    "    fp = open(data, 'rb')\n",
    "    rsrcmgr = PDFResourceManager()\n",
    "    retstr = io.StringIO()\n",
    "    codec = 'utf-8'\n",
    "    laparams = LAParams()\n",
    "    device = TextConverter(rsrcmgr, retstr, codec=codec, laparams=laparams)\n",
    "    # Create a PDF interpreter object.\n",
    "    interpreter = PDFPageInterpreter(rsrcmgr, device)\n",
    "    # Process each page contained in the document.\n",
    "\n",
    "    for page in PDFPage.get_pages(fp):\n",
    "        interpreter.process_page(page)\n",
    "        data =  retstr.getvalue()\n",
    "\n",
    "    return(data)\n",
    "\n",
    "#if __name__ == '__main__':\n",
    "#    pdfparser(sys.argv[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "output = pdfparser('M19-388PA15Mar19.pdf')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Protocol for Study M19-388\n",
      "\n",
      "Venetoclax Extension Study\n",
      "\n",
      "2.0\n",
      "\n",
      "AbbVie\n",
      "\n",
      "VERSION:\n",
      "\n",
      "SPONSOR:\n",
      "\n",
      "ABBVIE \n",
      "INVESTIGATIONAL \n",
      "PRODUCT:\n",
      "\n",
      "DATE:\n",
      "\n",
      "15 March 2019\n",
      "\n",
      "Venetoclax (ABT-199)\n",
      "\n",
      "EUDRACT:\n",
      "\n",
      "NUMBER OF SITES:\n",
      "\n",
      "Approximately 325 sites \n",
      "in 35 countries\n",
      "2018-004356-38\n",
      "\n",
      "FULL TITLE:  An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax \n",
      "Clinical Trial\n",
      "\n",
      "PRINCIPAL INVESTIGATOR(S):\n",
      "\n",
      "Investigator information on file at AbbVie.\n",
      "\n",
      "SPONSOR/EMERGENCY MEDICAL \n",
      "CONTACT:*\n",
      "\n",
      "Su Young Kim, MD, PhD\n",
      "AbbVie\n",
      "Dept. R48K, Bldg. AP30-3\n",
      "1 North Waukegan Road\n",
      "North Chicago, IL 60064\n",
      "\n",
      "Office:\n",
      "+1 (847) 937-4903\n",
      "Mobile: +1 (224) 360-4688\n",
      "+1 (847) 589-2024\n",
      "Fax:\n",
      "Email:\n",
      "su.kim@abbvie.com\n",
      "EMERGENCY 24 hour Number:  +1 973-784-6402\n",
      "\n",
      "*The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country \n",
      "are provided within the clinical trial agreement with the Investigator/Institution and in the Clinical Trial \n",
      "Application with the Competent Authority.  Additional study contact information can be found in the \n",
      "Operations Manual (Appendix F).\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 1 of 42\f",
      "TABLE OF CONTENTS\n",
      "\n",
      "1\n",
      "\n",
      "SYNOPSIS\n",
      "\n",
      "2\n",
      "2.1\n",
      "\n",
      "2.2\n",
      "\n",
      "INTRODUCTION\n",
      "\n",
      "BACKGROUND AND RATIONALE\n",
      "BENEFITS AND RISKS TO SUBJECTS\n",
      "\n",
      "STUDY OBJECTIVES AND ENDPOINTS\n",
      "\n",
      "3\n",
      "3.1 OBJECTIVES\n",
      "3.2\n",
      "\n",
      "EFFICACY ENDPOINTS\n",
      "SAFETY ENDPOINTS\n",
      "\n",
      "3.3\n",
      "\n",
      "INVESTIGATIONAL PLAN\n",
      "\n",
      "4\n",
      "4.1 OVERALL STUDY DESIGN AND PLAN\n",
      "4.2 DISCUSSION OF STUDY DESIGN\n",
      "\n",
      "5\n",
      "5.1\n",
      "\n",
      "5.2\n",
      "\n",
      "5.3\n",
      "\n",
      "STUDY ACTIVITIES\n",
      "ELIGIBILITY CRITERIA\n",
      "CONTRACEPTION RECOMMENDATIONS\n",
      "PROHIBITED MEDICATIONS AND THERAPY\n",
      "PRIOR AND CONCOMITANT THERAPY\n",
      "\n",
      "5.4\n",
      "5.5 WITHDRAWAL OF SUBJECTS AND DISCONTINUATION OF STUDY\n",
      "5.6\n",
      "\n",
      "FOLLOW-UP FOR SUBJECT WITHDRAWAL FROM STUDY\n",
      "STUDY DRUG\n",
      "RANDOMIZATION/DRUG ASSIGNMENT\n",
      "PROTOCOL DEVIATIONS\n",
      "\n",
      "SAFETY CONSIDERATIONS\n",
      "\n",
      "COMPLAINTS AND ADVERSE EVENTS\n",
      "TOXICITY MANAGEMENT\n",
      "\n",
      "5.7\n",
      "\n",
      "5.8\n",
      "\n",
      "5.9\n",
      "\n",
      "6\n",
      "6.1\n",
      "\n",
      "6.2\n",
      "\n",
      "STATISTICAL METHODS & DETERMINATION OF SAMPLE SIZE\n",
      "\n",
      "7\n",
      "7.1\n",
      "7.2 DEFINITION FOR ANALYSIS POPULATIONS\n",
      "\n",
      "STATISTICAL AND ANALYTICAL PLANS\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "4\n",
      "\n",
      "5\n",
      "5\n",
      "\n",
      "5\n",
      "\n",
      "5\n",
      "5\n",
      "\n",
      "5\n",
      "\n",
      "5\n",
      "\n",
      "6\n",
      "6\n",
      "\n",
      "6\n",
      "\n",
      "7\n",
      "7\n",
      "\n",
      "8\n",
      "\n",
      "10\n",
      "\n",
      "10\n",
      "\n",
      "11\n",
      "\n",
      "11\n",
      "\n",
      "12\n",
      "\n",
      "12\n",
      "\n",
      "12\n",
      "\n",
      "13\n",
      "13\n",
      "\n",
      "16\n",
      "\n",
      "16\n",
      "16\n",
      "\n",
      "16\n",
      "\n",
      "Page 2 of 42\f",
      "16\n",
      "\n",
      "16\n",
      "\n",
      "16\n",
      "\n",
      "17\n",
      "17\n",
      "\n",
      "17\n",
      "\n",
      "17\n",
      "\n",
      "17\n",
      "\n",
      "18\n",
      "\n",
      "18\n",
      "\n",
      "18\n",
      "\n",
      "12\n",
      "\n",
      "19\n",
      "\n",
      "20\n",
      "\n",
      "21\n",
      "\n",
      "22\n",
      "\n",
      "23\n",
      "\n",
      "24\n",
      "\n",
      "7.3 DETERMINATION OF SAMPLE SIZE\n",
      "7.4\n",
      "\n",
      "STATISTICAL ANALYSES FOR EFFICACY\n",
      "STATISTICAL ANALYSES FOR SAFETY\n",
      "\n",
      "7.5\n",
      "\n",
      "8\n",
      "8.1\n",
      "\n",
      "8.2\n",
      "\n",
      "8.3\n",
      "\n",
      "ETHICS\n",
      "\n",
      "INDEPENDENT ETHICS COMMITTEE/INSTITUTIONAL REVIEW BOARD (IEC/IRB)\n",
      "ETHICAL CONDUCT OF THE STUDY\n",
      "SUBJECT CONFIDENTIALITY\n",
      "\n",
      "9\n",
      "\n",
      "SOURCE DOCUMENTS AND CASE REPORT FORM COMPLETION\n",
      "\n",
      "10 DATA QUALITY ASSURANCE\n",
      "\n",
      "11 COMPLETION OF THE STUDY\n",
      "\n",
      "12 REFERENCES\n",
      "\n",
      "LIST OF TABLES\n",
      "\n",
      "TABLE 1.\n",
      "\n",
      "STUDY DRUG INFORMATION\n",
      "\n",
      "LIST OF APPENDICES\n",
      "\n",
      "APPENDIX A.\n",
      "\n",
      "STUDY SPECIFIC ABBREVIATIONS AND TERMS\n",
      "\n",
      "APPENDIX B.\n",
      "\n",
      "RESPONSIBILITIES OF THE INVESTIGATOR\n",
      "\n",
      "APPENDIX C.\n",
      "\n",
      "LIST OF PROTOCOL SIGNATORIES\n",
      "\n",
      "APPENDIX D.\n",
      "\n",
      "ACTIVITY SCHEDULE\n",
      "\n",
      "APPENDIX E.\n",
      "\n",
      "PROTOCOL SUMMARY OF CHANGES\n",
      "\n",
      "APPENDIX F.\n",
      "\n",
      "OPERATIONS MANUAL\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 3 of 42\f",
      "Title:  An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial\n",
      "Background and Rationale:\n",
      "\n",
      "1 SYNOPSIS\n",
      "\n",
      "Objective(s) and Endpoint(s):\n",
      "\n",
      "Investigator(s):\n",
      "Study Site(s):\n",
      "Study Population and Number of \n",
      "Subjects to be Enrolled:\n",
      "Investigational Plan:\n",
      "\n",
      "Key Eligibility Criteria:\n",
      "\n",
      "Study Drug and Duration of \n",
      "Treatment:\n",
      "\n",
      "Date of Protocol Synopsis:\n",
      "\n",
      "The purpose of this extension study is to provide venetoclax and obtain \n",
      "long-term safety data for subjects who continue to tolerate and derive \n",
      "benefit from receiving venetoclax in ongoing studies.\n",
      "Objective:  obtain long-term safety data for subjects rolling over from \n",
      "ongoing venetoclax studies.\n",
      "Endpoint:  adverse event collection.  There are no formal statistical \n",
      "analyses of safety data for this study.\n",
      "Multicenter\n",
      "Approximately 325 sites.\n",
      "Approximately 550 subjects.\n",
      "\n",
      "This is a Phase 3, open-label, multicenter, extension study.  Subjects \n",
      "will receive venetoclax daily until discontinuing from the study.  \n",
      "Subjects who are receiving other study agents at the time of study \n",
      "entry may continue to receive them, but these agents will not be \n",
      "supplied by AbbVie.  Subjects will be evaluated per the standard of \n",
      "care and will return every 12 weeks (± 2 weeks) to continue \n",
      "dispensation of venetoclax and evaluation of adverse events, serious \n",
      "adverse events, and use of concomitant medications.\n",
      "Subject has been enrolled and dosed in an ongoing venetoclax study \n",
      "and continues to tolerate and derive benefit from the study drug.  \n",
      "Male subjects must agree to refrain from sperm donation.  Female \n",
      "subjects must not be pregnant or breastfeeding.\n",
      "Subjects will continue to receive venetoclax orally, once daily, \n",
      "continuously at the same dosage strength administered to them during \n",
      "the previous study in which they were enrolled.\n",
      "Venetoclax (ABT-199) will be supplied as film-coated tables of 50 mg or \n",
      "100 mg dosage strengths.  Venetoclax will also be supplied as tablets \n",
      "for oral suspension at 2.5 mg, 10 mg, or 25 mg dosage strengths.\n",
      "Once venetoclax is approved and commercially available in the country \n",
      "of participation, AbbVie will not provide venetoclax or any other \n",
      "therapy once the subject's participation is concluded.\n",
      "15 March 2019\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 4 of 42\f",
      "2 INTRODUCTION\n",
      "2.1 Background and Rationale\n",
      "\n",
      "Why Is This Study Being Conducted\n",
      "AbbVie is developing a potent, selective, and orally bioavailable small molecule inhibitor of B-cell \n",
      "lymphoma (BCL)-2, venetoclax (also referred to as ABT-199, A-1195425.0, GDC-0199, RO5537382, \n",
      "Venclexta®, and Venclyxto®), that may address the current treatment needs for patients with chronic \n",
      "lymphocytic leukemia (CLL), acute myeloid leukemia (AML), multiple myeloma (MM), Non-Hodgkin's \n",
      "lymphoma (NHL), and acute lymphoblastic leukemia (ALL).  Additional details can be found in the \n",
      "Venetoclax Investigator's Brochure.1\n",
      "\n",
      "The purpose of this extension study is to provide venetoclax to, and obtain long-term safety data for, \n",
      "subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.\n",
      "\n",
      "Clinical Hypothesis\n",
      "No clinical hypotheses are being tested.\n",
      "2.2 Benefits and Risks to Subjects\n",
      "\n",
      "As of 28 November 2017, a total of 2,495 subjects have received treatment with venetoclax across \n",
      "company-sponsored clinical studies.  Efficacy and safety data from completed and ongoing studies \n",
      "support further development of venetoclax for subjects with CLL, AML, MM, NHL, and ALL.  For further \n",
      "details, refer to the Venetoclax Investigator's Brochure.1\n",
      "3 STUDY OBJECTIVES AND ENDPOINTS\n",
      "3.1 Objectives\n",
      "\n",
      "The primary objective is to obtain long-term safety data for subjects from ongoing venetoclax studies.\n",
      "3.2 Efficacy Endpoints\n",
      "\n",
      "There are no efficacy objectives or endpoints for this extension study.\n",
      "3.3 Safety Endpoints\n",
      "\n",
      "Safety evaluations include adverse event monitoring as a measure of safety and tolerability for the \n",
      "entire study duration.  All deaths on the study will also be collected.\n",
      "\n",
      "Adverse events will be collected from the time of enrollment until the end of the study.  All adverse \n",
      "events, regardless of seriousness or causality, will be reported through the Follow-up Period.  Details on \n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 5 of 42\f",
      "adverse event reporting are provided in Section 6.1 and in the Operations Manual, Section 4 \n",
      "(Appendix F).\n",
      "4 INVESTIGATIONAL PLAN\n",
      "4.1 Overall Study Design and Plan\n",
      "\n",
      "This is a Phase 3, open-label, multicenter, extension study.  Subjects will receive venetoclax daily until \n",
      "discontinuing from the study.  Subjects who are receiving other study agents at the time of study entry \n",
      "may continue to receive them, but these agents will not be supplied by AbbVie.  Subjects will be \n",
      "evaluated per the standard of care and will return every 12 weeks (± 2 weeks) to continue dispensation \n",
      "of venetoclax, as well as evaluation of adverse events and use of concomitant medications.\n",
      "\n",
      "When an investigator has determined that a subject should discontinue the study, a Safety Follow-up \n",
      "Visit will occur 30 days after the final dose of venetoclax.  If the subject discontinues the study due to \n",
      "toxicities attributable to venetoclax, additional follow-up visits may be conducted, as clinically \n",
      "appropriate, until a satisfactory clinical resolution of the adverse event is achieved.\n",
      "\n",
      "Further details regarding study procedures are located in the Operations Manual, Appendix F.  See \n",
      "Section 5 for information regarding eligibility criteria.\n",
      "4.2 Discussion of Study Design\n",
      "\n",
      "Choice of Control Group\n",
      "There is no control group in this extension study.\n",
      "\n",
      "Appropriateness of Measurements\n",
      "All clinical and laboratory procedures in this study are standard and generally accepted.\n",
      "\n",
      "Suitability of Subject Population\n",
      "All subjects enrolled within this study were previously enrolled and dosed in venetoclax studies.  These \n",
      "subjects would have met eligibility criteria for their prior study and will meet all of the eligibility criteria \n",
      "for this study.\n",
      "\n",
      "Selection of Doses in the Study\n",
      "Subjects in this study will continue to receive venetoclax at the same dose administered to them during \n",
      "the previous study in which they were enrolled.  If a subject previously required a dose reduction during \n",
      "the previous venetoclax study, then that reduced dose can be administered.  Dose reductions may also \n",
      "occur during treatment.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 6 of 42\f",
      "5 STUDY ACTIVITIES\n",
      "5.1 Eligibility Criteria\n",
      "\n",
      "Subjects must meet all of the following criteria in order to be included in the study.  Anything other than \n",
      "a positive response to the questions below will result in exclusion from study participation.\n",
      "\n",
      "Consent and Other General Criteria\n",
      "\n",
      "1. Subjects or their legally authorized representative must voluntarily sign and date an informed \n",
      "consent (assent if appropriate), approved by an independent ethics committee \n",
      "(IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific \n",
      "procedures.\n",
      "2. Subject has completed a prior venetoclax study, and the investigator believes that continued \n",
      "treatment with venetoclax is in the best interest of the patient.\n",
      "3. Subjects are willing or able to comply with procedures required in this protocol.\n",
      "4. Subjects entering the extension study with multiple myeloma must adhere to the following \n",
      "guidelines:\n",
      "\n",
      "\n",
      "All subjects receiving treatment with venetoclax in combination with a proteasome inhibitor \n",
      "must receive prophylaxis with antibiotics while on treatment and for at least 30 days after \n",
      "discontinuation of the proteasome inhibitor and/or venetoclax including:\n",
      "\n",
      " AND\n",
      "\n",
      "\n",
      "Bactrim forte® (1 tablet, 3 times a week) or equivalent antibiotic therapy,\n",
      "\n",
      "Amoxicillin clavulanate (500 mg to 1 g, twice daily) or levofloxacin (500 mg once daily, \n",
      "adjusted for renal function) or equivalent antibiotic therapy per institutional guidelines.\n",
      "If the patient has hypersensitivity to these agents or develops unacceptable toxicity or \n",
      "intolerance, the AbbVie Medical Monitor should be notified, followed by a discussion of \n",
      "the risk and benefits.\n",
      "The use of antibiotics that are moderate or strong cytochrome P450 (CYP) 3A4 inhibitors \n",
      "should be avoided or used with caution and with appropriate dose modification as per \n",
      "protocol.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "All subjects with MM receiving venetoclax should be closely monitored for infections, and in \n",
      "the event of a Grade ≥ 3 or serious infection, treatment with venetoclax should be \n",
      "interrupted and, upon resolution, treatment can be resumed at a reduced dose or \n",
      "discontinued, depending on the Investigator's clinical judgment.\n",
      "\n",
      " G-CSF (granulocyte-colony stimulating factor) should continue to be used for treatment of \n",
      "\n",
      "neutropenia according to the individual protocol or Institutional guidelines.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 7 of 42\f",
      "Contraception\n",
      "\n",
      "5. For all females of child-bearing potential; a negative urine pregnancy test during the \n",
      "Transition Visit, prior to the first dose of study drug during this extension study.\n",
      "6. Female subjects of childbearing potential must practice at least 1 protocol-specified method \n",
      "of birth control, which is effective from Study Day 1 through at least 30 days after the last dose \n",
      "of study drug.  Female subjects of non-childbearing potential do not need to use birth control.\n",
      "7. Female who is not pregnant, breastfeeding, or considering becoming pregnant during the \n",
      "study or for approximately 30 days after the last dose of study drug.\n",
      "8. If male, and subject is sexually active with female partner(s) of childbearing potential, he \n",
      "must agree, from Study Day 1 through 90 days after the last dose of study drug, to practice the \n",
      "protocol-specified contraception.\n",
      "9. Male who is not considering fathering a child or donating sperm during the study or for \n",
      "approximately 90 days after the last dose of study drug.\n",
      "\n",
      "5.2 Contraception Recommendations\n",
      "\n",
      "The contraception guidelines provided in this section are applicable to venetoclax only.  Investigators \n",
      "should review the contraception requirements per the local label of any concomitant medications \n",
      "administered to subjects within this study.\n",
      "\n",
      "Contraception Requirements for Females\n",
      "Subjects must follow the following contraceptive guidelines as specified:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Females, Non-Childbearing Potential\n",
      "Females do not need to use birth control during or following study drug treatment if considered \n",
      "of non-childbearing potential due to meeting any of the following criteria:\n",
      "\n",
      "\n",
      "Postmenopausal, age > 55 years with no menses for 12 or more months without an \n",
      "alternative medical cause.\n",
      "Postmenopausal, age ≤ 55 years with no menses for 12 or more months without an \n",
      "alternative medical cause AND a follicle-stimulating hormone level (FSH) > 40 IU/L.\n",
      "Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or \n",
      "hysterectomy).\n",
      "Females who have not experienced menarche (at least 1 menstrual period).\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Females, of Childbearing Potential\n",
      "\n",
      "\n",
      "Females of childbearing potential must avoid pregnancy while taking study drug(s) and for \n",
      "at least 30 days after the last dose of study drug.\n",
      "Females must commit to 1 of the following methods of birth control:\n",
      "\n",
      "\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 8 of 42\f",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Combined (estrogen- and progestogen-containing) hormonal birth control (oral, \n",
      "intravaginal, transdermal, or injectable) associated with inhibition of ovulation initiated \n",
      "at least 30 days prior to Study Day 1.\n",
      "Progestogen-only hormonal birth control (oral, injectable, implantable) associated with \n",
      "inhibition of ovulation initiated at least 30 days prior to Study Day 1.\n",
      "Bilateral tubal occlusion/ligation (can be via hysteroscopy, provided a \n",
      "hysterosalpingogram confirms success of the procedure).\n",
      "Intrauterine device (IUD).\n",
      "Intrauterine hormone-releasing system (IUS).\n",
      "Vasectomized partner (provided the partner has received medical confirmation of the \n",
      "surgical success of the vasectomy and is the sole sexual partner of the trial subject).\n",
      "Practice true abstinence, defined as:  Refraining from heterosexual intercourse when \n",
      "this is in line with the preferred and usual lifestyle of the subject (periodic abstinence \n",
      "[e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are \n",
      "not acceptable).\n",
      "\n",
      "Contraception recommendations related to use of concomitant therapies prescribed should be based on \n",
      "the local label.\n",
      "\n",
      "\n",
      "\n",
      "Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary \n",
      "mode of action, initiated at least 30 days prior to Study Day 1.\n",
      "\n",
      " Male or female condom with or without spermicide.\n",
      "\n",
      "\n",
      "\n",
      "Cap, diaphragm, or sponge with spermicide.\n",
      "A combination of male condom with cap, diaphragm, or sponge with spermicide (double-barrier \n",
      "method).\n",
      "\n",
      "Contraception Requirements for Males\n",
      "Male subjects who are sexually active with a female partner of childbearing potential, must agree to use \n",
      "condoms, even if the male subject has undergone a successful vasectomy, from Study Day 1 through at \n",
      "least 90 days after the last dose of study drug.  Male subjects must not donate sperm during study \n",
      "participation and for up to 90 days after discontinuing any study drug.\n",
      "\n",
      " His female partner(s) must also use at least 1 of the following methods of birth control:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Combined (estrogen- and progestogen-containing) hormonal birth control (oral, \n",
      "intravaginal, transdermal, injectable) associated with inhibition of ovulation initiated at least \n",
      "30 days prior to Study Day 1\n",
      "Progestogen-only hormonal birth control (oral, injectable, implantable) associated with \n",
      "inhibition of ovulation initiated at least 1 month prior to Study Day 1\n",
      "Bilateral tubal occlusion/ligation (can be via hysteroscopy, provided a hysterosalpingogram \n",
      "confirms success of the procedure)\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 9 of 42\f",
      "\n",
      "\n",
      "\n",
      "\n",
      "IUD\n",
      "IUS\n",
      "Vasectomized partner (provided the partner has received medical confirmation of the \n",
      "surgical success of the vasectomy, and is the sole sexual partner of the trial subject)\n",
      "\n",
      "5.3 Prohibited Medications and Therapy\n",
      "\n",
      "Strong and moderate inducers of cytochrome P450 (CYP) 3A are not allowed.\n",
      "\n",
      "For further details on prohibited medications and therapy for venetoclax, refer to Appendix B in the \n",
      "Operations Manual (Appendix F).\n",
      "5.4 Prior and Concomitant Therapy\n",
      "\n",
      "Subjects should receive full supportive care during study participation including transfusion of blood \n",
      "products, fluid and electrolyte replacement, and antibiotics, as appropriate.  Subjects using oral \n",
      "contraceptives, hormone-replacement therapy, or other maintenance therapy should continue their \n",
      "use.\n",
      "\n",
      "Any medication or vaccine (including over-the-counter or prescription medicines, vitamins, and/or \n",
      "herbal supplements) that the subject is receiving at the time of enrollment or receives during the study \n",
      "must be recorded through the Safety Follow-up Visit.\n",
      "\n",
      "CYP3A inhibitors and inducers should only be used when no appropriate therapeutic alternative exists.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "A strong inhibitor of CYP3A requires an 8-fold dose reduction of venetoclax\n",
      "A moderate inhibitor of CYP3A requires a 2-fold dose reduction of venetoclax\n",
      "\n",
      "The following drugs are cautionary throughout the treatment period:\n",
      "\n",
      "P-glycoprotein (P-gp) substrates\n",
      "Breast cancer resistance protein (BCRP) substrates\n",
      "\n",
      " Warfarin and coumarin derivatives\n",
      "\n",
      "\n",
      " Organic anion-transporting polypeptide (OATP) 1B1/1B3 substrates\n",
      "\n",
      "\n",
      "\n",
      "P-gp inhibitors\n",
      "BCRP inhibitors\n",
      "\n",
      "Consult the Operations Manual for specific examples of prohibited and cautionary medications that fall \n",
      "into these categories.  General guidelines regarding excluded and cautionary medications and dietary \n",
      "restrictions are summarized in the Operations Manual, Section 3.4.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 10 of 42\f",
      "Any questions regarding concomitant or prior therapy should be raised to the AbbVie emergency \n",
      "contact.  Information regarding potential drug interactions with venetoclax can be located in the \n",
      "Venetoclax Investigator's Brochure.1\n",
      "5.5 Withdrawal of Subjects and Discontinuation of Study\n",
      "\n",
      "A subject may voluntarily withdraw or be withdrawn from the study at any time for reasons including, \n",
      "but not limited to, the following:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Clinically significant abnormal laboratory results or adverse events, which rule out continuation \n",
      "of the study drug, as determined by the investigator or the AbbVie Therapeutic Area Medical \n",
      "Director.\n",
      "The subject requests withdrawal from the study.\n",
      "The investigator believes it is in the best interest of the subject.\n",
      "Subject is significantly noncompliant with study procedures, which would put the subject at risk \n",
      "for continued participation in the trial.\n",
      "Introduction of prohibited medications or dosages and continuation of the study drug would \n",
      "place the subject at risk.\n",
      "The subject becomes pregnant while on study drug.\n",
      "The subject is lost to follow-up or dies.\n",
      "The study is terminated by the Sponsor.\n",
      "Venetoclax is approved and reimbursable for the treated indication in the country of \n",
      "participation.\n",
      "\n",
      "For subjects to be considered lost to follow-up, reasonable attempts must be made to obtain \n",
      "information on the subject's final status.  At a minimum, 2 telephone calls must be made and 1 certified \n",
      "letter must be sent and documented in the subject's source documentation.\n",
      "\n",
      "AbbVie may terminate this study prematurely, either in its entirety or at any site.  The investigator may \n",
      "also stop the study at her/his site if she/he has safety concerns.  If AbbVie terminates the study for \n",
      "safety reasons, AbbVie will promptly notify the investigator.\n",
      "5.6 Follow-Up for Subject Withdrawal from Study\n",
      "\n",
      "If a subject prematurely discontinues study participation (withdrawal of informed consent), a Safety \n",
      "Follow-up Visit or phone call will occur 30 days after the last dose of venetoclax and will be completed \n",
      "to ensure all treatment-emergent adverse events/serious adverse events have been resolved.  If the \n",
      "subject discontinues the study due to toxicities attributable to venetoclax, additional follow-up visits \n",
      "may be conducted, as clinically appropriate, until a satisfactory clinical resolution of the adverse event is \n",
      "achieved.  Subjects should be advised on the continued scientific importance of their data even if they \n",
      "discontinue treatment with study drug early.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 11 of 42\f",
      "5.7 Study Drug\n",
      "\n",
      "Venetoclax, manufactured by AbbVie, will be taken orally, once daily, continuously beginning on Study \n",
      "Day 1 and should be taken at approximately the same time each day (Table 1).\n",
      "\n",
      "The subject will be instructed to return all drug containers (even if empty) to the study site personnel at \n",
      "each study visit.  The study site personnel will document compliance.\n",
      "\n",
      "AbbVie will provide study drug for venetoclax.  AbbVie-provided study drug should not be substituted or \n",
      "alternately sourced unless otherwise directed by AbbVie.\n",
      "\n",
      "Venetoclax will be packaged in blisters or bottles with quantities sufficient to accommodate study \n",
      "design.  Each kit will be labeled per local requirements, and this label must remain affixed to the kit.  Site \n",
      "staff will complete all blank spaces on the label before dispensing to subjects.  Study drug will only be \n",
      "used for the conduct of this study.\n",
      "Table 1.\n",
      "\n",
      "Study Drug Information\n",
      "\n",
      "Investigational \n",
      "Product\n",
      "Venetoclax (ABT-199)\n",
      "Venetoclax (ABT-199)\n",
      "\n",
      "Manufacturer\n",
      "\n",
      "Mode of \n",
      "\n",
      "Administration\n",
      "\n",
      "AbbVie\n",
      "AbbVie\n",
      "\n",
      "Oral\n",
      "Oral\n",
      "\n",
      "5.8 Randomization/Drug Assignment\n",
      "\n",
      "Dosage Form\n",
      "\n",
      "Film-coated tablets\n",
      "\n",
      "Dose Strength\n",
      "50 or 100 mg\n",
      "\n",
      "Tablets for oral suspension\n",
      "\n",
      "2.5, 10, or 25 mg\n",
      "\n",
      "This is an open-label study.  There is no randomization for this study.\n",
      "\n",
      "All subjects will be assigned a unique identification number by the Interactive Response Technology \n",
      "(IRT) at the Transition Visit (refer to the Operations Manual, Section 6.3).\n",
      "5.9 Protocol Deviations\n",
      "\n",
      "The investigator is responsible for complying with all protocol requirements, written instructions, and \n",
      "applicable laws regarding protocol deviations.  Protocol deviations are prohibited except when \n",
      "necessary to eliminate an immediate hazard to study subjects.  If a protocol deviation occurs (or is \n",
      "identified), the investigator is responsible for notifying Independent Ethics Committee \n",
      "(IEC)/Independent Review Board (IRB), regulatory authorities (as applicable), and AbbVie.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 12 of 42\f",
      "6 SAFETY CONSIDERATIONS\n",
      "6.1 Complaints and Adverse Events\n",
      "\n",
      "Complaints\n",
      "A complaint is any written, electronic, or oral communication that alleges deficiencies related to the \n",
      "physical characteristics, identity, quality, purity, potency, durability, reliability, safety, effectiveness, or \n",
      "performance of a product/device.  Complaints associated with any component of this investigational \n",
      "product must be reported to AbbVie.\n",
      "\n",
      "Product Complaint\n",
      "A product complaint is any complaint related to the biologic or drug component of the product or to the \n",
      "medical device component(s).\n",
      "\n",
      "For a product this may include, but is not limited to, damaged/broken product or packaging, product \n",
      "appearance whose color/markings do not match the labeling, labeling discrepancies/inadequacies in the \n",
      "labeling/instructions (e.g., printing illegible), missing components/product, device not working properly, \n",
      "or packaging issues.\n",
      "\n",
      "Product complaints concerning the investigational product and/or device must be reported to AbbVie \n",
      "within 1 business day of the study site's knowledge of the event.  Product complaints occurring during \n",
      "the study will be followed up to a satisfactory conclusion.\n",
      "\n",
      "Medical Complaints/Adverse Events and Serious Adverse Events\n",
      "An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation \n",
      "subject administered a pharmaceutical product and which does not necessarily have a causal \n",
      "relationship with this treatment.  An adverse event can therefore be any unfavorable and unintended \n",
      "sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use \n",
      "of a medicinal (investigational) product, whether or not the event is considered causally related to the \n",
      "use of the product.\n",
      "\n",
      "The investigators will monitor each subject for clinical and laboratory evidence of adverse events on a \n",
      "routine basis throughout the study.  All adverse events will be followed to a satisfactory conclusion.\n",
      "\n",
      "An elective surgery/procedure scheduled to occur during a study will not be considered an adverse \n",
      "event if the surgery/procedure is being performed for a pre-existing condition and the \n",
      "surgery/procedure has been pre planned prior to study entry.  However, if the pre-existing condition \n",
      "deteriorates unexpectedly during the study (e.g., surgery performed earlier than planned), then the \n",
      "deterioration of the condition for which the elective surgery/procedure is being done will be considered \n",
      "an adverse event.\n",
      "\n",
      "If an adverse event, whether associated with study drug or not, meets any of the following criteria, it is \n",
      "to be reported to AbbVie clinical pharmacovigilance or CRO (as appropriate) as a serious adverse event \n",
      "within 24 hours of the site being made aware of the serious adverse event (refer to Section 4.3 of the \n",
      "Operations Manual for reporting details and contact information):\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 13 of 42\f",
      "Death of Subject\n",
      "\n",
      "Life-Threatening\n",
      "\n",
      "Hospitalization or \n",
      "Prolongation of \n",
      "Hospitalization\n",
      "\n",
      "Congenital Anomaly\n",
      "\n",
      "Persistent or Significant \n",
      "Disability/Incapacity\n",
      "\n",
      "Important Medical Event \n",
      "Requiring Medical or \n",
      "Surgical Intervention to \n",
      "Prevent Serious Outcome\n",
      "\n",
      "An event that results in the death of a subject.\n",
      "\n",
      "An event that, in the opinion of the investigator, would have resulted \n",
      "in immediate fatality if medical intervention had not been taken.  This \n",
      "does not include an event that would have been fatal if it had occurred \n",
      "in a more severe form.\n",
      "\n",
      "An event that results in an admission to the hospital for any length of \n",
      "time or prolongs the subject's hospital stay.  This does not include an \n",
      "emergency room visit or admission to an outpatient facility.\n",
      "\n",
      "An anomaly detected at or after birth, or any anomaly that results in \n",
      "fetal loss.\n",
      "\n",
      "An event that results in a condition that substantially interferes with \n",
      "the activities of daily living of a study subject.  Disability is not intended \n",
      "to include experiences of relatively minor medical significance such as \n",
      "headache, nausea, vomiting, diarrhea, influenza, and accidental trauma \n",
      "(e.g., sprained ankle).\n",
      "\n",
      "An important medical event that may not be immediately life-\n",
      "threatening or result in death or hospitalization, but based on medical \n",
      "judgment may jeopardize the subject and may require medical or \n",
      "surgical intervention to prevent any of the outcomes listed above \n",
      "(i.e., death of subject, life threatening, hospitalization, prolongation of \n",
      "hospitalization, congenital anomaly, or persistent or significant \n",
      "disability/incapacity).  Additionally, any elective or spontaneous \n",
      "abortion or stillbirth is considered an important medical event.  \n",
      "Examples of such events include allergic bronchospasm requiring \n",
      "intensive treatment in an emergency room or at home, blood \n",
      "dyscrasias or convulsions that do not result in inpatient hospitalization, \n",
      "or the development of drug dependency or drug abuse.\n",
      "\n",
      "All adverse events reported from the time of study drug administration until 30 days after \n",
      "discontinuation of study drug administration will be collected, whether solicited or spontaneously \n",
      "reported by the subject.  In addition, serious adverse events and protocol-related nonserious adverse \n",
      "events will be collected from the time the subject signs the study-specific informed consent.\n",
      "\n",
      "AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions (SUSAR) reporting for \n",
      "the Investigational Medicinal Product (IMP) in accordance with global and local requirements.\n",
      "\n",
      "Adverse events will be monitored throughout the study to identify any of special interest that may \n",
      "indicate a trend or risk to subjects.\n",
      "\n",
      "Adverse Event Severity and Relationship to Study Drug\n",
      "The investigators will rate the severity of each adverse event according to the National Cancer Institute \n",
      "(NCI) Common Terminology Criteria for Adverse Events (CTCAE).  If a reported adverse event increases \n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 14 of 42\f",
      "in severity, the initial adverse event should be given an outcome date and a new adverse event must be \n",
      "reported on a different onset date than the end date of the previous adverse event to reflect the change \n",
      "in severity.  The dates on the adverse events cannot overlap.  For all reported serious adverse events \n",
      "that increase in severity, the supplemental electronic case report forms (eCRFs) also need to be updated \n",
      "to reflect any changes due to the increase in severity.\n",
      "\n",
      "For adverse events not captured by the NCI CTCAE, the following should be used:\n",
      "\n",
      "Grade 1\n",
      "Grade 2\n",
      "\n",
      "Grade 3\n",
      "\n",
      "Grade 4\n",
      "Grade 5\n",
      "\n",
      "The adverse event is transient and easily tolerated by the subject (mild).\n",
      "The adverse event causes the subject discomfort and interrupts the subject's usual activities \n",
      "(moderate).\n",
      "The adverse event causes considerable interference with the subject's usual activities and \n",
      "may be incapacitating (moderate to severe).\n",
      "The adverse event is life-threatening and requires urgent intervention (severe).\n",
      "The adverse event resulted in death of the subject (severe).\n",
      "\n",
      "The investigator will use the following definitions to assess the relationship of the adverse event to the \n",
      "use of study drug:\n",
      "\n",
      "Reasonable \n",
      "Possibility\n",
      "\n",
      "No Reasonable \n",
      "Possibility\n",
      "\n",
      "After consideration of factors including timing of the event, biologic \n",
      "plausibility, clinical judgment, and potential alternative causes, there is \n",
      "sufficient evidence (information) to suggest a causal relationship.\n",
      "\n",
      "After consideration of factors including timing of the event, biologic \n",
      "plausibility, clinical judgment, and potential alternative causes, there is \n",
      "insufficient evidence (information) to suggest a causal relationship.\n",
      "\n",
      "Pregnancy\n",
      "While not an adverse event, pregnancy in a study subject must be reported to AbbVie within 1 working \n",
      "day after the site becomes aware of the pregnancy.  Subjects who become pregnant during the study \n",
      "must be discontinued (Section 5.5).  If a pregnancy occurs in a study subject or in the partner of a study \n",
      "subject, information regarding the pregnancy and the outcome will be collected.\n",
      "\n",
      "In the event of pregnancy occurring in a subject's partner during the study, written informed consent \n",
      "from the partner must be obtained prior to collection of any such information.  AbbVie will provide a \n",
      "separate consent form for this purpose.  Pregnancy in a subject's partners will be collected from the \n",
      "date of the first dose through 30 days following the last dose of study drug.\n",
      "\n",
      "The pregnancy outcome of an elective or spontaneous abortion, stillbirth or congenital anomaly is \n",
      "considered a serious adverse event and must be reported to AbbVie within 24 hours after the site \n",
      "becomes aware of the event.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 15 of 42\f",
      "6.2 Toxicity Management\n",
      "\n",
      "Venetoclax can cause rapid reduction in tumors and, thus, poses a risk for Tumor Lysis Syndrome (TLS) in \n",
      "the initial 5-week ramp-up phase.  Depending on the specific tumor type, risk factors may include one or \n",
      "more of the following:  bulky disease or high tumor burden, renal insufficiency, splenomegaly, elevated \n",
      "pretreatment lactate dehydrogenase levels, elevated leukocyte count, and dehydration.  Changes in \n",
      "electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours \n",
      "following the first dose of treatment.  TLS prophylaxis and management will be provided to subjects per \n",
      "standard-of-care based on institutional guidelines.\n",
      "\n",
      "Management of Other Toxicities\n",
      "If other events occur that are related to venetoclax, the investigator may interrupt or reduce the dose of \n",
      "venetoclax.  Grade 3 or greater non-hematological toxicity (e.g., nausea, vomiting, and diarrhea when \n",
      "additional supportive care fails or neurotoxicity, aspartate aminotransferase, alanine aminotransferase, \n",
      "or bilirubin increased), that is related to venetoclax will require interruption and possible \n",
      "discontinuation of dosing.  Venetoclax may be reintroduced, but only at a reduced dose if the toxicity \n",
      "returns to ≤ Grade 1 or to baseline if Grade 2 at study entry.\n",
      "7 STATISTICAL METHODS & DETERMINATION OF SAMPLE SIZE\n",
      "7.1 Statistical and Analytical Plans\n",
      "\n",
      "A Statistical Analysis Plan (SAP) for the safety assessments will be written.  Data and listings will be \n",
      "produced for future use.  No interim analysis is planned or will be performed.\n",
      "7.2 Definition for Analysis Populations\n",
      "\n",
      "The primary analysis set consists of all subjects who were enrolled and received at least 1 dose of study \n",
      "drug, unless specified otherwise.\n",
      "7.3 Determination of Sample Size\n",
      "\n",
      "There is no minimum or maximum sample size for this study.\n",
      "7.4 Statistical Analyses for Efficacy\n",
      "\n",
      "No efficacy analyses will be performed for this study.\n",
      "7.5 Statistical Analyses for Safety\n",
      "\n",
      "Adverse events will be coded and summarized by system organ class and preferred term (and severity) \n",
      "according to the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1 or higher.  Clinical \n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 16 of 42\f",
      "toxicity grades modified from the NCI CTCAE will be used in the grading of adverse events and \n",
      "laboratory abnormalities that are reported as adverse events.  The version to be used for the NCI CTCAE \n",
      "ratings will remain consistent with the parent study from which the subject was rolled over.  Serious \n",
      "adverse events related to treatment will also be summarized.  Additional details on the safety \n",
      "assessments will be provided in the SAP.\n",
      "\n",
      "An Unscheduled Visit should be performed when the subject comes in for a medical visit for evaluation \n",
      "and assessment related to an adverse event/serious adverse event.  Additional details are provided in \n",
      "the Operations Manual, Section 3.7.  Definitions of adverse events are provided in Section 6.1 and in the \n",
      "Operations Manual, Section 4.\n",
      "8 ETHICS\n",
      "8.1 Independent Ethics Committee/Institutional Review Board \n",
      "\n",
      "(IEC/IRB)\n",
      "\n",
      "The protocol, informed consent form(s), recruitment materials, and all subject materials will be \n",
      "submitted to the IEC/IRB for review and approval.  Approval of both the protocol and the informed \n",
      "consent form(s) must be obtained before any subject is enrolled.  Any amendment to the protocol will \n",
      "require review and approval by the IEC/IRB before the changes are implemented to the study.  In \n",
      "addition, all changes to the consent form(s) will be IEC/IRB approved.\n",
      "8.2 Ethical Conduct of the Study\n",
      "\n",
      "The study will be conducted in accordance with the protocol, Operations Manual, International Council \n",
      "for Harmonisation (ICH) guidelines, applicable regulations, and guidelines governing clinical study \n",
      "conduct and the ethical principles that have their origin in the Declaration of Helsinki.  Responsibilities of \n",
      "the investigator are specified in Appendix B.\n",
      "8.3 Subject Confidentiality\n",
      "\n",
      "To protect subjects' confidentiality, all subjects and their associated samples will be assigned numerical \n",
      "study identifiers or \"codes.\"  No identifiable information will be provided to AbbVie.\n",
      "9 SOURCE DOCUMENTS AND CASE REPORT FORM \n",
      "\n",
      "COMPLETION\n",
      "\n",
      "The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the \n",
      "data reported.  All source documents should be attributable, legible, contemporaneous, original, \n",
      "accurate, and complete to ensure accurate interpretation of data.  Clinical site monitoring is conducted \n",
      "to ensure that the rights and well-being of human subjects are protected, that the reported trial data \n",
      "are accurate, complete, and verifiable, and that the conduct of the trial is in compliance with the \n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 17 of 42\f",
      "currently approved protocol, ICH Good Clinical Practice (GCP), and applicable local regulatory \n",
      "requirement(s).\n",
      "10 DATA QUALITY ASSURANCE\n",
      "\n",
      "AbbVie will ensure that the clinical trial is conducted with a quality management system that will define \n",
      "quality tolerance limits in order to ensure human subject protection and reliability of study results.  Data \n",
      "will be generated, documented, and reported in compliance with the protocol, ICH GCP, and applicable \n",
      "regulatory requirements.\n",
      "11 COMPLETION OF THE STUDY\n",
      "\n",
      "The end-of-study will occur when subjects experience death or discontinue the study for other reasons, \n",
      "or if AbbVie terminates the study.  AbbVie may close the study in certain countries once venetoclax is \n",
      "approved and reimbursable for the treated indication in the country of participation.\n",
      "12 REFERENCES\n",
      "\n",
      "1. AbbVie.  Venetoclax Investigator's Brochure Edition 9.  08 March 2018.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 18 of 42\f",
      "APPENDIX A. STUDY SPECIFIC ABBREVIATIONS AND TERMS\n",
      "\n",
      "Abbreviation\n",
      "\n",
      "Definition\n",
      "\n",
      "ALL\n",
      "AML\n",
      "BCRP\n",
      "CLL\n",
      "CTCAE\n",
      "CYP\n",
      "CYP3A\n",
      "GCP\n",
      "ICH\n",
      "IEC\n",
      "IRB\n",
      "IUD\n",
      "IUS\n",
      "MM\n",
      "NCI\n",
      "NHL\n",
      "P-gp\n",
      "SAP\n",
      "SUSAR\n",
      "TLS\n",
      "\n",
      "acute lymphoblastic leukemia\n",
      "acute myeloid leukemia\n",
      "breast cancer resistance protein\n",
      "chronic lymphocytic leukemia\n",
      "Common Terminology Criteria for Adverse Events\n",
      "cytochrome P450\n",
      "cytochrome P450 3A isoform subfamily\n",
      "Good clinical practice\n",
      "International Council for Harmonisation\n",
      "Independent ethics committee\n",
      "Institutional review board1\n",
      "intrauterine device\n",
      "Intrauterine hormone-releasing system\n",
      "multiple myeloma\n",
      "National Cancer Institute\n",
      "non-Hodgkin lymphoma\n",
      "P-glycoprotein\n",
      "Statistical analysis plan\n",
      "Suspected unexpected serious adverse reactions\n",
      "Tumor Lysis Syndrome\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 19 of 42\f",
      "APPENDIX B. RESPONSIBILITIES OF THE INVESTIGATOR\n",
      "\n",
      "Protocol M19-388:  Venetoclax Extension Study\n",
      "\n",
      "Protocol Date:  15 March 2019\n",
      "\n",
      "Clinical research studies sponsored by AbbVie are subject to the International Council for Harmonisation \n",
      "(ICH) Good Clinical Practices (GCP) and local regulations and guidelines governing the study at the site \n",
      "location.  In signing the Investigator Agreement, the investigator is agreeing to the following:\n",
      "\n",
      "1. Conducting the study in accordance with ICH GCP, the applicable regulatory requirements, \n",
      "\n",
      "current protocol and operations manual, and making changes to a protocol only after notifying \n",
      "AbbVie and the appropriate Institutional Review Board (IRB)/Independent Ethics Committee \n",
      "(IEC), except when necessary to protect the subject from immediate harm.\n",
      "\n",
      "2. Personally conducting or supervising the described investigation(s).\n",
      "3.\n",
      "\n",
      "Informing all subjects, or persons used as controls, that the drugs are being used for \n",
      "investigational purposes and complying with the requirements relating to informed consent and \n",
      "ethics committees (e.g., IEC or IRB) review and approval of the protocol and its amendments.\n",
      "\n",
      "4. Reporting complaints that occur in the course of the investigation(s) to AbbVie.\n",
      "5. Reading the information in the Investigator's Brochure/safety material provided, including the \n",
      "\n",
      "instructions for use and the potential risks and side effects of the investigational product(s).\n",
      "Informing all associates, colleagues, and employees assisting in the conduct of the study about \n",
      "their obligations in meeting the above commitments.\n",
      "\n",
      "6.\n",
      "\n",
      "7. Maintaining adequate and accurate records of the conduct of the study, making those records \n",
      "available for inspection by representatives of AbbVie and/or the appropriate regulatory agency, \n",
      "and retaining all study-related documents until notification from AbbVie.\n",
      "\n",
      "8. Maintaining records demonstrating that an ethics committee reviewed and approved the initial \n",
      "\n",
      "clinical protocol and all of its amendments.\n",
      "\n",
      "9. Reporting promptly, all changes in the research activity and all unanticipated problems involving \n",
      "risks to human subjects or others, to the appropriate individuals (e.g., coordinating investigator, \n",
      "institution director) and/or directly to the ethics committees and AbbVie.\n",
      "\n",
      "10. Providing direct access to source data documents for study-related monitoring, audits, IEC/IRB \n",
      "\n",
      "review, and regulatory inspection(s).\n",
      "\n",
      "Signature of Principal Investigator\n",
      "\n",
      "Date\n",
      "\n",
      "Name of Principal Investigator (printed or typed)\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 20 of 42\f",
      "APPENDIX C. LIST OF PROTOCOL SIGNATORIES\n",
      "\n",
      "Name\n",
      "Paulo Maciaj\n",
      "Jennifer Arzt\n",
      "Todd Busman\n",
      "Tessy Sebastian\n",
      "\n",
      "Title\n",
      "Senior Medical Director\n",
      "Study Project Manager\n",
      "Director, Statistics\n",
      "Senior Medical Writer\n",
      "\n",
      "Functional Area\n",
      "Clinical Development\n",
      "Clinical Program Development\n",
      "Data and Statistical Sciences\n",
      "Medical Writing\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 21 of 42\f",
      "APPENDIX D. ACTIVITY SCHEDULE\n",
      "\n",
      "The following table shows the required activities for this study.  The individual activities are described in \n",
      "detail in the Operations Manual.\n",
      "\n",
      "Study Activities Table\n",
      "\n",
      " \n",
      "\n",
      "t\n",
      "i\n",
      "s\n",
      "i\n",
      "V\n",
      "n\n",
      "o\n",
      "i\n",
      "t\n",
      "i\n",
      "s\n",
      "n\n",
      "a\n",
      "r\n",
      "T\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "INTERVIEWS & QUESTIONNAIRES\n",
      "\n",
      "Informed consent\n",
      "\n",
      "Eligibility criteria\n",
      "\n",
      "Adverse event assessment\n",
      "\n",
      "Prior/concomitant therapy\n",
      "\n",
      "LOCAL LABS & EXAMS\n",
      "\n",
      "Urine pregnancy test (for women of childbearing potential)\n",
      "\n",
      "TREATMENT\n",
      "\n",
      "Dispense study drug\n",
      "\n",
      "Perform drug reconciliation\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "2\n",
      "1\n",
      "y\n",
      "r\n",
      "e\n",
      "v\n",
      "E\n",
      " \n",
      "f\n",
      "o\n",
      "1\n",
      "y\n",
      "a\n",
      "D\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      " \n",
      ")\n",
      "s\n",
      "k\n",
      "e\n",
      "e\n",
      "w\n",
      "2\n",
      "±\n",
      "(\n",
      " \n",
      "s\n",
      "k\n",
      "e\n",
      "e\n",
      "w\n",
      "\n",
      " \n",
      "\n",
      "r\n",
      "e\n",
      "t\n",
      "f\n",
      "a\n",
      "e\n",
      "r\n",
      "e\n",
      "h\n",
      "t\n",
      "\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "1\n",
      "y\n",
      "a\n",
      "D\n",
      "y\n",
      "d\n",
      "u\n",
      "t\n",
      "S\n",
      "\n",
      " \n",
      "\n",
      "p\n",
      "u\n",
      "-\n",
      "w\n",
      "o\n",
      "\n",
      "l\n",
      "l\n",
      "\n",
      " \n",
      "\n",
      "o\n",
      "F\n",
      "y\n",
      "a\n",
      "D\n",
      "-\n",
      "0\n",
      "3\n",
      "\n",
      "l\n",
      "l\n",
      "\n",
      "a\n",
      "C\n",
      "/\n",
      "t\n",
      "i\n",
      "s\n",
      "i\n",
      "V\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 22 of 42\f",
      "APPENDIX E. PROTOCOL SUMMARY OF CHANGES\n",
      "\n",
      "Previous Protocol Versions\n",
      "\n",
      "Protocol\n",
      "Version 1.0\n",
      "\n",
      "Date\n",
      "12 December 2018\n",
      "\n",
      "The purpose of this Version is to correct minor clerical errors for consistency throughout the protocol in \n",
      "addition to the following:\n",
      "\n",
      "Rationale\n",
      "To reduce the risk of subjects \n",
      "entering the study with \n",
      "ongoing infections.\n",
      "\n",
      "Details of Changes Made\n",
      "Updated Section 5.1, Eligibility Criteria, by adding Criterion #4.\n",
      "This criterion sets safety guidelines for subjects with MM entering the \n",
      "extension study including:\n",
      "(1) all subjects must receive prophylaxis with antibiotics while on treatment \n",
      "and for at least 30 days after discontinuation of study treatment;\n",
      "(2) all subjects must be closely monitored for infections, and events of \n",
      "Grade ≥ 3 or serious infections are to treated by interrupting venetoclax; and\n",
      "(3) G-CSF should continue to be used as a treatment for neutropenia.\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 23 of 42\f",
      "APPENDIX F. OPERATIONS MANUAL\n",
      "\n",
      "STUDY M19-388  |  Version 2.0 / EudraCT 2018-004356-38\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 24 of 42\f",
      "Operations Manual for Clinical Study Protocol M19-388\n",
      "\n",
      "Venetoclax Extension Study\n",
      "\n",
      "SPONSOR:\n",
      "\n",
      "AbbVie\n",
      "\n",
      "ABBVIE INVESTIGATIONAL \n",
      "PRODUCT:\n",
      "\n",
      "Venetoclax (ABT-199)\n",
      "\n",
      "FULL TITLE:  An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 1 of 16\n",
      "\n",
      "Page 25 of 42\f",
      "1 CONTACTS\n",
      "\n",
      "Sponsor/\n",
      "Emergency \n",
      "Medical Contact\n",
      "\n",
      "Su Young Kim, MD, PhD\n",
      "AbbVie\n",
      "1 North Waukegan Road\n",
      "North Chicago, IL 60064\n",
      "\n",
      "Office:\n",
      "+1 (847) 937-4903\n",
      "Mobile: +1 (224) 360-4688\n",
      "+1 (847) 589-2024\n",
      "Fax:\n",
      "Email:\n",
      "su.kim@abbvie.com\n",
      "\n",
      "Safety Concerns\n",
      "\n",
      "EMERGENCY 24 hour Number:  \n",
      "+1 (973) 784-6402\n",
      "\n",
      "Oncology Safety Team\n",
      "Dept. R48S, Bldg. AP30\n",
      "1 North Waukegan Road\n",
      "North Chicago, IL 60064\n",
      "\n",
      "+1 (847) 935-2609\n",
      "\n",
      "Phone:\n",
      "Email:\n",
      "SafetyManagement_Oncology@abbvie.com\n",
      "\n",
      "SAE Reporting \n",
      "outside of RAVE\n",
      "\n",
      "Email:\n",
      "PPDINDPharmacovigilance@abbvie.com\n",
      "\n",
      "Fax:\n",
      "\n",
      "+1 (847) 938-0660\n",
      "\n",
      "Protocol \n",
      "Deviations\n",
      "\n",
      "Jennifer Arzt\n",
      "AbbVie\n",
      "1 North Waukegan Road\n",
      "North Chicago, IL 60064\n",
      "\n",
      "Phone:\n",
      "Fax:\n",
      "Email:\n",
      "\n",
      "+1 (847) 938-8165\n",
      "+1 (847) 937-7812\n",
      "jennifer.arzt@abbvie.com\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 2 of 16\n",
      "\n",
      "Page 26 of 42\f",
      "TABLE OF CONTENTS\n",
      "\n",
      "1\n",
      "\n",
      "CONTACTS\n",
      "\n",
      "PROTOCOL ACTIVITIES BY VISIT\n",
      "\n",
      "INDIVIDUAL TREATMENT PERIOD VISIT ACTIVITIES\n",
      "INDIVIDUAL POST-TREATMENT PERIOD VISIT ACTIVITIES\n",
      "\n",
      "STUDY PROCEDURES\n",
      "\n",
      "SUBJECT INFORMATION AND INFORMED CONSENT\n",
      "ADVERSE EVENT ASSESSMENT\n",
      "\n",
      "3.2\n",
      "3.3 DISPENSE STUDY DRUG\n",
      "3.4\n",
      "\n",
      "CONCOMITANT MEDICATION\n",
      "CLINICAL LABORATORY TESTS\n",
      "SUBJECT WITHDRAWAL FROM STUDY\n",
      "\n",
      "3.6\n",
      "3.7 UNSCHEDULED VISITS\n",
      "\n",
      "SAFETY MANUAL\n",
      "\n",
      "4\n",
      "4.1 METHODS AND TIMING OF SAFETY ASSESSMENT\n",
      "4.2\n",
      "\n",
      "RECORDING DATA AND ANALYSES OF SAFETY FINDINGS\n",
      "REPORTING ADVERSE EVENTS AND INTERCURRENT ILLNESSES\n",
      "\n",
      "COUNTRY-SPECIFIC REQUIREMENTS\n",
      "\n",
      "SAMPLE RETENTION REQUIREMENTS\n",
      "SUSAR REPORTING\n",
      "TREATMENT AFTER END OF STUDY\n",
      "\n",
      "STUDY DRUG\n",
      "\n",
      "TREATMENTS ADMINISTERED\n",
      "PACKAGING AND LABELING\n",
      "\n",
      "6.2\n",
      "6.3 METHOD OF ASSIGNING SUBJECTS TO TREATMENT GROUPS\n",
      "6.4\n",
      "\n",
      "SELECTION AND TIMING OF DOSE FOR EACH SUBJECT\n",
      "\n",
      "2\n",
      "2.1\n",
      "\n",
      "2.2\n",
      "\n",
      "3\n",
      "3.1\n",
      "\n",
      "3.5\n",
      "\n",
      "4.3\n",
      "\n",
      "5\n",
      "5.1\n",
      "\n",
      "5.2\n",
      "\n",
      "5.3\n",
      "\n",
      "6\n",
      "6.1\n",
      "\n",
      "2\n",
      "\n",
      "5\n",
      "5\n",
      "\n",
      "6\n",
      "\n",
      "6\n",
      "6\n",
      "\n",
      "6\n",
      "\n",
      "6\n",
      "\n",
      "7\n",
      "\n",
      "7\n",
      "\n",
      "8\n",
      "\n",
      "8\n",
      "\n",
      "8\n",
      "8\n",
      "\n",
      "9\n",
      "\n",
      "9\n",
      "\n",
      "10\n",
      "10\n",
      "\n",
      "11\n",
      "\n",
      "11\n",
      "\n",
      "11\n",
      "11\n",
      "\n",
      "12\n",
      "\n",
      "12\n",
      "\n",
      "12\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 3 of 16\n",
      "\n",
      "Page 27 of 42\f",
      "LIST OF APPENDICES\n",
      "\n",
      "APPENDIX A.\n",
      "\n",
      "STUDY SPECIFIC ABBREVIATIONS AND TERMS\n",
      "\n",
      "APPENDIX B.\n",
      "\n",
      "SAMPLE LIST OF PROHIBITED AND CAUTIONARY MEDICATIONS\n",
      "\n",
      "APPENDIX C.\n",
      "\n",
      "PREPARATION AND RECONSTITUTION OF VENETOCLAX TABLETS FOR ORAL SUSPENSION\n",
      "\n",
      "13\n",
      "\n",
      "14\n",
      "\n",
      "15\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 4 of 16\n",
      "\n",
      "Page 28 of 42\f",
      "2 PROTOCOL ACTIVITIES BY VISIT\n",
      "2.1 Individual Treatment Period Visit Activities\n",
      "\n",
      "This section presents a list of activities performed during each visit, organized by visit.  The dot pattern \n",
      "on the upper right indicates the place of the visit in the overall Treatment Period Activity Schedule.\n",
      "\n",
      "Activities are grouped by category (Interview, Exam, etc.).  Further information about each activity is \n",
      "provided in Section 3.\n",
      "TRANSITION VISIT:\n",
      "\n",
      "  INTERVIEW\n",
      "\n",
      "  EXAM\n",
      "\n",
      "Informed consent\n",
      "Eligibility criteria\n",
      "\n",
      "\n",
      "\n",
      " Urine pregnancy test\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Adverse event assessment\n",
      "Prior/concomitant therapy\n",
      "\n",
      "NOTES:\n",
      "\n",
      "A urine pregnancy test will be performed on site at the Transition visit, prior to the \n",
      "first dose of study drug on Day 1.\n",
      "\n",
      "DAY 1:\n",
      "\n",
      "  INTERVIEW\n",
      "\n",
      "  TREATMENT\n",
      "\n",
      "\n",
      "\n",
      "Adverse event assessment\n",
      "\n",
      "\n",
      "\n",
      "Prior/concomitant therapy\n",
      "\n",
      " Dispense study drug\n",
      "\n",
      "DAY 1 OF EVERY 12 WEEKS THEREAFTER:\n",
      "\n",
      "  INTERVIEW\n",
      "\n",
      "  TREATMENT\n",
      "\n",
      "\n",
      "\n",
      "Adverse event assessment\n",
      "\n",
      " Dispense study drug\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Prior/concomitant therapy\n",
      "\n",
      "Perform drug reconciliation\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 5 of 16\n",
      "\n",
      "Page 29 of 42\f",
      "2.2 Individual Post-Treatment Period Visit Activities\n",
      "\n",
      "This section presents a list of activities performed during the visit.  Further information about the \n",
      "activities is presented in Section 3.\n",
      "30-DAY POST-TREATMENT PERIOD FOLLOW-UP:\n",
      "\n",
      "  INTERVIEW\n",
      "\n",
      "\n",
      "\n",
      "Adverse event assessment\n",
      "\n",
      "\n",
      "\n",
      "Prior/concomitant therapy\n",
      "\n",
      "3 STUDY PROCEDURES\n",
      "3.1 Subject Information and Informed Consent\n",
      "\n",
      "The investigator or her/his representative will explain the nature of the study to the subject and answer \n",
      "all questions regarding this study.  Prior to any study-related transition procedures being performed on \n",
      "the subject or any medications being discontinued by the subject in order to participate in this study, \n",
      "the informed consent statement will be reviewed, signed, and dated by the subject or their legally \n",
      "authorized representative, the person who administered the informed consent, and any other \n",
      "signatories according to local requirements.  A copy of the signed informed consent will be given to the \n",
      "subject and the original will be placed in the subject's medical record.  An entry must also be made in \n",
      "the subject's dated source documents to confirm that informed consent was obtained prior to any \n",
      "study-related procedures and that the subject received a signed copy.\n",
      "\n",
      "Information regarding benefits for subjects and information regarding provisions for treating and/or \n",
      "compensating subjects who are harmed as a consequence of participation in the study can be found in \n",
      "the informed consent form.\n",
      "3.2 Adverse Event Assessment\n",
      "\n",
      "Please refer to Section 4.2.\n",
      "3.3 Dispense Study Drug\n",
      "\n",
      "Venetoclax will be dispensed to subjects beginning at Study Day 1 and as specified in Section 2.1.  The \n",
      "first dose of study drug will be administered after all other Day 1 procedures are completed.  At the \n",
      "visits specified in Section 2.1, the site personnel will review returned study drug kits and empty study \n",
      "drug packaging to verify compliance.\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 6 of 16\n",
      "\n",
      "Page 30 of 42\f",
      "3.4 Concomitant Medication\n",
      "\n",
      "If a subject reports taking any over-the-counter or prescription medications, vitamins and/or herbal \n",
      "supplements or if administration of any medication becomes necessary beginning with the transition \n",
      "visit through 30 days after last dose of study drug, the name of the medication, dosage information \n",
      "including dose, route, and frequency, date(s) of administration including start and end dates, and reason \n",
      "for use must be recorded on the appropriate electronic Case Report Form (eCRF).\n",
      "\n",
      "Prohibited and cautionary concomitant medications are provided in Protocol Section 5.3 and \n",
      "Section 5.4.  Although cautionary, use of strong or moderate cytochrome P450 (CYP3) A inhibitors are \n",
      "allowed if no appropriate therapeutic alternative exists.  Dose reductions of venetoclax are required \n",
      "with concomitant administration of a strong or moderate CYP3A inhibitor (refer to the Protocol \n",
      "Section 5.4).  Alternative treatments with less CYP3A inhibition should be considered.\n",
      "\n",
      "A sample list of prohibited medications and cautionary medications that may interact with study drug is \n",
      "provided in Appendix A.  It is not possible to produce a complete list of medications that fall into these \n",
      "categories; if in question, please refer to the product label.\n",
      "\n",
      "For guidance regarding medications for management of neutropenia, refer to the Protocol Section 6.2.  \n",
      "The AbbVie Therapeutic Area Medical Director (TA MD) identified in Section 1 should be contacted if \n",
      "there are any questions regarding concomitant or prior therapy(ies).\n",
      "3.5 Clinical Laboratory Tests\n",
      "\n",
      "Pregnancy Tests (Urine)\n",
      "Pregnancy testing should not be performed for postmenopausal women.  A urine or serum pregnancy \n",
      "test will be performed at the Transition Visit for all female subjects of childbearing potential (as defined \n",
      "in the protocol).  Pregnancy testing should not be performed for postmenopausal women.\n",
      "\n",
      "If the pregnancy test is:\n",
      "\n",
      "Positive, the subject is considered a screen failure;\n",
      "\n",
      " Negative, the subject can be enrolled into the trial;\n",
      "\n",
      "\n",
      "Still borderline ≥ 3 days later, this will be considered documentation of continued lack of a \n",
      "positive result and the subject can be enrolled into the study (unless prohibited per local \n",
      "requirements) in the absence of clinical suspicion of pregnancy and other pathological causes of \n",
      "borderline results.\n",
      "\n",
      "More frequent pregnancy tests can be performed throughout the study at the investigator's discretion \n",
      "or if required per local/country requirements.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "If the baseline pregnancy test is negative, then dosing with study drug may begin.\n",
      "If the baseline or post-baseline pregnancy test is positive, dosing with study drug must be \n",
      "withheld and a repeat pregnancy test is required.\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 7 of 16\n",
      "\n",
      "Page 31 of 42\f",
      " Unless a woman is suspected to have become pregnant, additional pregnancy testing during the \n",
      "\n",
      "clinical trial is not necessary.\n",
      "\n",
      "3.6 Subject Withdrawal from Study\n",
      "\n",
      "All attempts must be made to determine the date of the last study drug dose and the primary reason for \n",
      "discontinuation of study drug or study participation.  The information will be recorded on the \n",
      "appropriate eCRF page.  However, these procedures should not interfere with the initiation of any new \n",
      "treatments or therapeutic modalities that the investigator feels are necessary to treat the subject's \n",
      "condition.  Following discontinuation of study drug, the subject will be treated in accordance with the \n",
      "investigator's best clinical judgment, irrespective of whether or not the subject decides to continue \n",
      "participation in the study.\n",
      "3.7 Unscheduled Visits\n",
      "\n",
      "An Unscheduled Visit should be performed when the subject comes in for a medical visit for evaluation \n",
      "and assessment related to an adverse event/serious adverse event.  During Unscheduled Visits, blood \n",
      "and/or urine samples may be obtained for the laboratory tests or for other tests done related to an \n",
      "adverse event/serious adverse event, at the investigator's discretion.  Any other assessments would be \n",
      "performed as standard-of-care.\n",
      "\n",
      "Visits for dispensing new study drug in case of temperature excursion, loss or damage are not \n",
      "considered an Unscheduled Visit.\n",
      "4 SAFETY MANUAL\n",
      "4.1 Methods and Timing of Safety Assessment\n",
      "\n",
      "All serious adverse events as well as protocol-related nonserious adverse events (e.g., infection at liver \n",
      "biopsy site, done during transition) will be collected from the time the subject signed the study-specific \n",
      "informed consent until study drug administration.  From the time of study drug administration until \n",
      "30 days after discontinuation of study treatment, all adverse events, regardless of seriousness, will be \n",
      "collected whether solicited or spontaneously reported by the subject.  After 30 days following \n",
      "completion of study treatment and throughout the Post-Treatment Period, all spontaneously reported \n",
      "serious adverse events will be collected (nonserious adverse events will not be collected).\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 8 of 16\n",
      "\n",
      "Page 32 of 42\f",
      "SAEs and\n",
      "\n",
      "Protocol-Related \n",
      "Nonserious AEs\n",
      "\n",
      "SAEs and Nonserious AEs\n",
      "\n",
      "Elicited and/or Spontaneously Reported\n",
      "\n",
      "Consent\n",
      "Signed\n",
      "\n",
      "Study Drug \n",
      "\n",
      "Start\n",
      "\n",
      "Study Drug \n",
      "Stopped\n",
      "\n",
      "30 Days After \n",
      "Study Drug \n",
      "Stopped\n",
      "\n",
      "AE = adverse event; SAE = serious adverse event\n",
      "4.2 Recording Data and Analyses of Safety Findings\n",
      "\n",
      "Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).  The \n",
      "number and percentage of subjects with treatment-emergent adverse events (i.e., any event that begins \n",
      "or worsens in severity after initiation of study drug through 30 days post-study drug dosing) will be \n",
      "tabulated by primary MedDRA System Organ Class (SOC) and preferred term (PT).  The tabulation of the \n",
      "number of subjects with treatment-emergent adverse events by severity grade and relationship to study \n",
      "drug also will be provided.  Subjects reporting more than 1 adverse event for a given MedDRA preferred \n",
      "term will be counted only once for that term using the most severe grade according to the severity \n",
      "grade table and the most related according to the relationship to study drug tables.  Subjects reporting \n",
      "more than 1 type of event within an SOC will be counted only once for that SOC.\n",
      "4.3 Reporting Adverse Events and Intercurrent Illnesses\n",
      "\n",
      "In the event of a serious adverse event, whether associated with study drug or not, the investigator will \n",
      "notify Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious adverse \n",
      "event by entering the serious adverse event data into the electronic data capture (EDC) system.  Serious \n",
      "adverse events that occur prior to the site having access to the RAVE® system, or if RAVE is not operable, \n",
      "should be documented on the serious adverse event non-CRF forms and emailed (preferred route) or \n",
      "faxed to Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious adverse \n",
      "event.\n",
      "\n",
      "Email:  PPDINDPharmacovigilance@abbvie.com\n",
      "FAX to:  +1 (847) 938-0660\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 9 of 16\n",
      "\n",
      "Page 33 of 42\f",
      "For safety concerns, contact the Oncology Safety Team at:\n",
      "Oncology Safety Team\n",
      "Dept. R48S, Bldg. AP30\n",
      "1 North Waukegan Road\n",
      "North Chicago, Illinois 60064\n",
      "Office:\n",
      "+1 (847) 935-2609\n",
      "SafetyManagement_Oncology@abbvie.com\n",
      "Email:\n",
      "\n",
      "For any subject safety concerns, please contact the physician listed below:\n",
      "Primary Therapeutic Area Medical Director\n",
      "EMERGENCY MEDICAL CONTACT: \n",
      "Su Young Kim, MD, PhD\n",
      "AbbVie \n",
      "Dept. R48K, Bldg. AP30-3\n",
      "1 North Waukegan Road\n",
      "North Chicago, IL 60064\n",
      "\n",
      "Contact Information:\n",
      "+1 (847) 937-4903\n",
      "Office: \n",
      "Mobile: +1 (224) 360-4688\n",
      "+1 (847) 589-2024\n",
      "Fax: \n",
      "Email:\n",
      "su.kim@abbvie.com\n",
      "\n",
      "In emergency situations involving study subjects when the primary Therapeutic Area Medical Director is \n",
      "not available by phone, please contact the 24-hour AbbVie Medical Escalation Hotline where your call \n",
      "will be re-directed to a designated backup AbbVie Therapeutic Area Medical Director:\n",
      "\n",
      "HOTLINE:  +1 (973) 784-6402\n",
      "\n",
      "The sponsor will be responsible for Suspected Unexpected Serious Adverse Reactions (SUSAR) reporting \n",
      "for the Investigational Medicinal Product (IMP) in accordance with Directive 2001/20/EC.\n",
      "5 COUNTRY-SPECIFIC REQUIREMENTS\n",
      "5.1 Sample Retention Requirements\n",
      "\n",
      "This is not applicable for this extension study.\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 10 of 16\n",
      "\n",
      "Page 34 of 42\f",
      "5.2 SUSAR Reporting\n",
      "\n",
      "AbbVie will be responsible for SUSAR reporting for the IMP in accordance with global and local \n",
      "guidelines and Appendix A of the Investigator Brochure will serve as the Reference Safety Information \n",
      "(RSI).  The RSI in effect at the start of a DSUR reporting period serves as the RSI during the reporting \n",
      "period.  For follow-up reports, the RSI in place at the time of occurrence of the 'suspected' Serious \n",
      "Adverse Reaction will be used to assess expectedness.\n",
      "5.3 Treatment After End of Study\n",
      "\n",
      "Subjects will continue on venetoclax treatment throughout the study until premature discontinuation of \n",
      "study drug or study termination by AbbVie.  At the subject's last study visit, the investigator will discuss \n",
      "the appropriate subsequent treatment with the subject.  Once venetoclax is approved and commercially \n",
      "available in the country of participation, AbbVie will not provide venetoclax or any other therapy once \n",
      "the subject's participation is concluded.\n",
      "6 STUDY DRUG\n",
      "6.1 Treatments Administered\n",
      "\n",
      "Venetoclax will be dispensed in the form of 50- and 100-mg film-coated tablets or in the form of 2.5-, \n",
      "10-, or 25-mg tablets for oral suspension (refer to the Protocol Section 5.7) at the visits listed in \n",
      "Section 2.1.\n",
      "\n",
      "Each dose of venetoclax tablets will be taken with approximately 240 mL of water.  The tablets for oral \n",
      "suspension must be prepared into liquid suspension within 60 minutes prior to dosing.  Subjects will be \n",
      "trained to self-administer venetoclax orally once daily within 30 minutes after the completion of \n",
      "breakfast or the subject's first meal of the day.\n",
      "\n",
      "Venetoclax tablets should be taken together and swallowed whole and not chewed, crushed, or broken \n",
      "prior to swallowing.  If a subject should forget to take her/his venetoclax dose at her/his regularly \n",
      "scheduled dosing time, the subject should take the forgotten dose as soon as she/he remembers, \n",
      "provided that the dose will be taken within 8 hours of the missed dose.  Otherwise, the subject should \n",
      "take the next dose at the next scheduled dosing time.  If the subject vomits with 15 minutes of taking \n",
      "venetoclax and all expelled tablets are still intact, another dose may be administered.\n",
      "\n",
      "The tablets for oral suspension should not be prepared into liquid suspension in advance for storage.  \n",
      "Details on the preparation of the oral suspension are provided in Appendix C.\n",
      "\n",
      "AbbVie will provide study drug for venetoclax.  AbbVie provided study drug should not be substituted or \n",
      "alternately sourced unless otherwise directed by AbbVie.\n",
      "\n",
      "Study drug must not be dispensed without contacting the interactive response technology (IRT) system.  \n",
      "Study drug may only be dispensed to subjects enrolled in the study through the IRT system.  At the end \n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 11 of 16\n",
      "\n",
      "Page 35 of 42\f",
      "of the Treatment Period or at the Premature Discontinuation visit, the site will contact the IRT system to \n",
      "provide visit date information and study drug return information for each kit.\n",
      "6.2 Packaging and Labeling\n",
      "\n",
      "The venetoclax tablets will be packaged in high density polyethylene (HDPE) plastic bottles or blister \n",
      "cards to accommodate the study design.  The venetoclax tablets for oral suspension will be packaged in \n",
      "blister cards.\n",
      "\n",
      "Each bottle or blister card will be labeled per country or local regulatory requirements, and this label \n",
      "must remain affixed to the kit.  Upon receipt, study drug should be stored as specified on the label and \n",
      "kept in a secure location.  Each kit will contain a unique kit number.  This kit number is assigned to a \n",
      "subject via IRT and encodes the appropriate study drug to be dispensed at the subject's corresponding \n",
      "study visit.  Site staff will complete all blank spaces on the label before dispensing to subjects.  Study \n",
      "drug will only be used for the conduct of this study.\n",
      "\n",
      "Storage and Disposition of Study Drug\n",
      "Venetoclax must be stored at controlled room temperature (15° to 25°C/59° to 77°F).\n",
      "\n",
      "The investigational products are for investigational use only and are to be used only within the context \n",
      "of this study.  The study drug supplied for this study must be maintained under adequate security and \n",
      "stored under the conditions specified on the label until dispensed for subject use, destroyed on site, or \n",
      "returned to AbbVie, as appropriate.\n",
      "6.3 Method of Assigning Subjects to Treatment Groups\n",
      "\n",
      "This is a non-randomized, open-label study.  All eligible subjects will receive venetoclax daily, as \n",
      "described in Section 2.1.\n",
      "\n",
      "At the Transition visit, all subjects will be assigned a unique subject number through the use of the IRT.  \n",
      "For subjects who do not meet the study selection criteria, the site personnel must contact the IRT \n",
      "system and identify the subject as a screen failure.\n",
      "\n",
      "Subjects who are enrolled will retain their subject number assigned at the transition visit throughout the \n",
      "study.  Upon receipt of study drug, the site will acknowledge receipt in the IRT system.\n",
      "\n",
      "Contact information and user guidelines for IRT use will be provided to each site.\n",
      "6.4 Selection and Timing of Dose for Each Subject\n",
      "\n",
      "Selection of the doses for this study is discussed in the study protocol, Section 4.2.  All tablets of \n",
      "venetoclax will be dosed together, every day for 12 week cycles.  All subjects should take all doses of the \n",
      "study drug with food around the same time each day, as described in Section 6.1.\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 12 of 16\n",
      "\n",
      "Page 36 of 42\f",
      "APPENDIX A. STUDY SPECIFIC ABBREVIATIONS AND TERMS\n",
      "\n",
      "Abbreviation\n",
      "\n",
      "Definition\n",
      "\n",
      "CYP\n",
      "eCRF\n",
      "HDPE\n",
      "IMP\n",
      "IRT\n",
      "PT\n",
      "RSI\n",
      "SOC\n",
      "SUSAR\n",
      "\n",
      "Cytochrome P450\n",
      "Electronic case report form\n",
      "High density polyethylene\n",
      "Investigational medical product\n",
      "Interactive response technology\n",
      "Preferred term\n",
      "Reference Safety Information\n",
      "System organ class\n",
      "Suspected unexpected serious adverse reaction\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 13 of 16\n",
      "\n",
      "Page 37 of 42\f",
      "APPENDIX B. SAMPLE LIST OF PROHIBITED AND CAUTIONARY\n",
      "\n",
      "MEDICATIONS\n",
      "\n",
      "Prohibited\n",
      "Strong CYP3A inducers – avasimibe, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St John's \n",
      "wort\n",
      "Moderate CYP3A inducers – bosentan, efavirenz, etravirine, modafinil, nafcillin\n",
      "Cautionary\n",
      "Strong CYP3A inhibitors – boceprevir, clarithromycin, cobicistat, conivaptan, danoprevir/ritonavir, \n",
      "elvitegravir/ritonavir, idelalisib,* indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, \n",
      "nefazodone, nelfinavir, paritaprevir/ritonavir combinations, posaconazole, ritonavir, saquinavir, telaprevir, \n",
      "telithromycin, tipranavir/ritonavir, troleandomycin, voriconazole\n",
      "Moderate CYP3A inhibitors – amprenavir, aprepitant, atazanavir, cimetidine, ciprofloxacin, clotrimazole, \n",
      "crizotinib,* cyclosporine,* darunavir/ritonavir, diltiazem,a dronedarone, erythromycin, fluconazole, \n",
      "fluvoxamine, fosamprenavir, imatinib,* isavuconazole, tofisopam, verapamil\n",
      "Warfarin and coumarin derivativesb\n",
      "P-gp substrates – aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus,* fexofenadine, \n",
      "lapatinib,* loperamide, maraviroc, nilotinib,* ranolazine, saxagliptin, sirolimus,* sitagliptin, talinolol, tolvaptan, \n",
      "topotecan*\n",
      "P-gp inhibitors – amiodarone, captopril, carvedilol, felodipine, propafenone, quercetin, quinidine, ronalzine, \n",
      "ticagrelor\n",
      "OATP1B1/1B3 substrates – atrasentan, cerivastatin, docetaxel, ezetimibe, fluvastatin, glyburide, nateglinide, \n",
      "paclitaxel, rosuvastatin, pravastatin, repaglinide, simvastatin acid, telmisartan, valsartan, olmesartan\n",
      "BCRP sensitive substrates – methotrexate,* mitoxantrone,* irinotecan,* lapatinib,* rosuvastatin, sulfasalazine, \n",
      "topotecan*\n",
      "BCRP inhibitors – geftinib,* curcumin\n",
      "BCRP = breast cancer resistance protein; CYP = cytochrome P450; FDA = Food and Drug Administration; OATP = organic anion-\n",
      "transporting polypeptide; P-gp = P-glycoprotein; USPI = United States package insert\n",
      "a. Moderate CYP3A inhibitor per venetoclax FDA USPI.\n",
      "Closely monitor the international normalized ratio.\n",
      "b.\n",
      "*\n",
      "These are anticancer agents; consult contact the AbbVie Therapeutic Area Medical Director before use.\n",
      "Note:\n",
      "\n",
      "This is not an exhaustive list.  For an updated list, see the following link:\n",
      "http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093\n",
      "664.htm\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 14 of 16\n",
      "\n",
      "Page 38 of 42\f",
      "APPENDIX C. PREPARATION AND RECONSTITUTION OF\n",
      "\n",
      "VENETOCLAX TABLETS FOR ORAL SUSPENSION\n",
      "\n",
      "Tablets for oral suspension should be reconstituted in the volume of water, 100% grape juice, or 100% \n",
      "apple juice as shown in the table below.  The liquids are not provided.\n",
      "\n",
      "Dose (mg)\n",
      "\n",
      "2.5\n",
      "5\n",
      "7.5\n",
      "10\n",
      "15\n",
      "20\n",
      "25\n",
      "30\n",
      "40\n",
      "50\n",
      "60\n",
      "70\n",
      "75\n",
      "80\n",
      "100\n",
      "120\n",
      "150\n",
      "170\n",
      "200\n",
      "250\n",
      "300\n",
      "350\n",
      "400\n",
      "500\n",
      "600\n",
      "700\n",
      "800\n",
      "\n",
      "Container\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "30 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "120 mL cup\n",
      "\n",
      "Dose Volume* \n",
      "\n",
      "Rinse Volume 1* \n",
      "\n",
      "Rinse Volume 2* \n",
      "\n",
      "Total Volume \n",
      "\n",
      "(mL)\n",
      "\n",
      "(mL)\n",
      "\n",
      "(mL)\n",
      "\n",
      "(mL)\n",
      "\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "10\n",
      "10\n",
      "10\n",
      "15\n",
      "15\n",
      "15\n",
      "20\n",
      "20\n",
      "25\n",
      "30\n",
      "40\n",
      "40\n",
      "50\n",
      "60\n",
      "70\n",
      "80\n",
      "100\n",
      "120\n",
      "140\n",
      "160\n",
      "\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "5\n",
      "10\n",
      "10\n",
      "10\n",
      "10\n",
      "10\n",
      "10\n",
      "10\n",
      "10\n",
      "10\n",
      "10\n",
      "\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "2\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "N/A\n",
      "\n",
      "9\n",
      "9\n",
      "9\n",
      "9\n",
      "9\n",
      "9\n",
      "9\n",
      "14\n",
      "14\n",
      "15\n",
      "20\n",
      "20\n",
      "20\n",
      "25\n",
      "25\n",
      "30\n",
      "35\n",
      "50\n",
      "50\n",
      "60\n",
      "70\n",
      "80\n",
      "90\n",
      "110\n",
      "130\n",
      "150\n",
      "170\n",
      "\n",
      "N/A = not applicable.\n",
      "* Minimum volume required for doses and rinses.\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 15 of 16\n",
      "\n",
      "Page 39 of 42\f",
      "Reconstitution and administration for the tablets for oral suspension, as follows:\n",
      "\n",
      "1. Gather your supplies.\n",
      "2. Add the required volume of liquid (water or juice) to the provided dosing cup.\n",
      "\n",
      "\n",
      "\n",
      "If the assigned dose is 600 mg or higher, add half of the required volume of liquid.  Follow \n",
      "Steps 2 to 7 for the first half and then repeat for the second half.\n",
      "\n",
      "3. Select the row(s) for the appropriate day (Day 1, Day 2 etc.) and push the black semi-circle all \n",
      "\n",
      "the way through the card, turn the card over and remove the childproof backing.\n",
      "\n",
      "4. Carefully push the venetoclax tablets through the back of the blister cards, one by one, directly \n",
      "into the dosing cup.  Ensure the total number of tablets for the daily dose is dispensed into the \n",
      "dosing cup.\n",
      "\n",
      "\n",
      "If the assigned dose is 600 mg or higher, add half of the total required tablets to the volume \n",
      "added in Step 2.\n",
      "\n",
      "5. Securely apply the dosing cup lid and wait 10 to 15 minutes.\n",
      "6. Shake well, approximately 3 to 10 minutes, or until no tablet fragments are seen when swirling \n",
      "\n",
      "the solution.\n",
      "\n",
      "7. Patient should drink the solution directly from the dosing cup.  An oral dosing syringe may be \n",
      "\n",
      "used for patients who cannot drink from the dosing cup.  If the patient is administered oral \n",
      "suspension via tube support, follow your institutional guidelines for administration.\n",
      "\n",
      "\n",
      "If the assigned dose is 600 mg or higher, repeat steps 2 to 7 for the second half of the dose \n",
      "before doing the rinse steps.\n",
      "\n",
      "8. Add the first rinse volume to the dosing cup.  Shake well and give to the patient.\n",
      "9. Repeat Step 8 for the second rinse (if required).  A dosing syringe is provided for rinse volumes \n",
      "\n",
      "less than 5 mL.\n",
      "If assigned dose is 600 mg or higher, half the dose should be prepared at the same time (in \n",
      "2 separate dosing cups).  The suggested rinse steps to ensure the rinse is completed as required:\n",
      "First rinse volume should be poured into cup 1, swirled to rinse the cup, poured into cup 2, \n",
      "\n",
      "swirled to rinse the cup, and administered.\n",
      "\n",
      "Patient must take all of the solution and rinses within 60 minutes of preparation.  Blister cards will be \n",
      "provided to patients based on the appropriate dose assignment along with detailed dosing instructions.\n",
      "\n",
      "If a tablet for oral suspension or the prepared suspension touches any surface, this surface should be \n",
      "cleaned with a wet disposable cloth or towel because staining can occur.\n",
      "\n",
      "OPERATIONS MANUAL FOR CLINICAL STUDY PROTOCOL M19-388 Version 2.0\n",
      "CONFIDENTIAL INFORMATION\n",
      "No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "p. 16 of 16\n",
      "\n",
      "Page 40 of 42\f",
      "Document Approval\n",
      "\n",
      "Study M19388 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax\n",
      "\n",
      "Clinical Trial - Operations Manual for Protocol Version 2-0 - 15Mar2019\n",
      "\n",
      "                                                                                                                                            \n",
      "\n",
      "Version: \n",
      "\n",
      "1.0\n",
      "\n",
      "       Date: \n",
      "\n",
      "15-Mar-2019 05:48:46 PM\n",
      "\n",
      "  Company ID: \n",
      "\n",
      "03152019-00F9F68412D199-00001-en\n",
      "\n",
      "Signed by:\n",
      "\n",
      "Maciag_Paulo\n",
      "\n",
      "Date:\n",
      "15-Mar-2019 03:38:18 PM\n",
      "\n",
      "Busman_Todd_A\n",
      "\n",
      "15-Mar-2019 03:56:57 PM\n",
      "\n",
      "Sebastian_Tessy\n",
      "\n",
      "15-Mar-2019 05:38:22 PM\n",
      "\n",
      "Arzt_Jennifer_A\n",
      "\n",
      "15-Mar-2019 05:48:46 P\n",
      "\n",
      "Meaning Of Signature:\n",
      "\n",
      "Approver\n",
      "\n",
      "Approver\n",
      "\n",
      "Author\n",
      "\n",
      "Approver\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 41 of 42\f",
      "Document Approval\n",
      "\n",
      "Study M19388 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax\n",
      "\n",
      "Clinical Trial - Protocol Version 2-0 - EudraCT 2018-004356-38 - 15Mar2019\n",
      "\n",
      "                                                                                                                                            \n",
      "\n",
      "Version: \n",
      "\n",
      "1.0\n",
      "\n",
      "       Date: \n",
      "\n",
      "15-Mar-2019 05:48:50 PM\n",
      "\n",
      "  Company ID: \n",
      "\n",
      "03152019-00F9F68412D196-00001-en\n",
      "\n",
      "Signed by:\n",
      "\n",
      "Maciag_Paulo\n",
      "\n",
      "Date:\n",
      "15-Mar-2019 03:38:18 PM\n",
      "\n",
      "Busman_Todd_A\n",
      "\n",
      "15-Mar-2019 03:56:57 PM\n",
      "\n",
      "Sebastian_Tessy\n",
      "\n",
      "15-Mar-2019 05:38:22 PM\n",
      "\n",
      "Arzt_Jennifer_A\n",
      "\n",
      "15-Mar-2019 05:48:46 P\n",
      "\n",
      "Meaning Of Signature:\n",
      "\n",
      "Approver\n",
      "\n",
      "Approver\n",
      "\n",
      "Author\n",
      "\n",
      "Approver\n",
      "\n",
      "VV-TMF-3347647 M19-388  Protocol Amendment - 15 Mar 2019 - Final Copy\n",
      "\n",
      "Page 42 of 42\f",
      "\n"
     ]
    }
   ],
   "source": [
    "print(output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Protocol',\n",
       " 'for',\n",
       " 'Study',\n",
       " 'M19-388',\n",
       " 'Venetoclax',\n",
       " 'Extension',\n",
       " 'Study',\n",
       " '2.0',\n",
       " 'AbbVie',\n",
       " 'VERSION',\n",
       " ':',\n",
       " 'SPONSOR',\n",
       " ':',\n",
       " 'ABBVIE',\n",
       " 'INVESTIGATIONAL',\n",
       " 'PRODUCT',\n",
       " ':',\n",
       " 'DATE',\n",
       " ':',\n",
       " '15',\n",
       " 'March',\n",
       " '2019',\n",
       " 'Venetoclax',\n",
       " '(',\n",
       " 'ABT-199',\n",
       " ')',\n",
       " 'EUDRACT',\n",
       " ':',\n",
       " 'NUMBER',\n",
       " 'OF',\n",
       " 'SITES',\n",
       " ':',\n",
       " 'Approximately',\n",
       " '325',\n",
       " 'sites',\n",
       " 'in',\n",
       " '35',\n",
       " 'countries',\n",
       " '2018-004356-38',\n",
       " 'FULL',\n",
       " 'TITLE',\n",
       " ':',\n",
       " 'An',\n",
       " 'Extension',\n",
       " 'Study',\n",
       " 'of',\n",
       " 'Venetoclax',\n",
       " 'for',\n",
       " 'Subjects',\n",
       " 'Who',\n",
       " 'Have',\n",
       " 'Completed',\n",
       " 'a',\n",
       " 'Prior',\n",
       " 'Venetoclax',\n",
       " 'Clinical',\n",
       " 'Trial',\n",
       " 'PRINCIPAL',\n",
       " 'INVESTIGATOR',\n",
       " '(',\n",
       " 'S',\n",
       " ')',\n",
       " ':',\n",
       " 'Investigator',\n",
       " 'information',\n",
       " 'on',\n",
       " 'file',\n",
       " 'at',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'SPONSOR/EMERGENCY',\n",
       " 'MEDICAL',\n",
       " 'CONTACT',\n",
       " ':',\n",
       " '*',\n",
       " 'Su',\n",
       " 'Young',\n",
       " 'Kim',\n",
       " ',',\n",
       " 'MD',\n",
       " ',',\n",
       " 'PhD',\n",
       " 'AbbVie',\n",
       " 'Dept',\n",
       " '.',\n",
       " 'R48K',\n",
       " ',',\n",
       " 'Bldg',\n",
       " '.',\n",
       " 'AP30-3',\n",
       " '1',\n",
       " 'North',\n",
       " 'Waukegan',\n",
       " 'Road',\n",
       " 'North',\n",
       " 'Chicago',\n",
       " ',',\n",
       " 'IL',\n",
       " '60064',\n",
       " 'Office',\n",
       " ':',\n",
       " '+1',\n",
       " '(',\n",
       " '847',\n",
       " ')',\n",
       " '937-4903',\n",
       " 'Mobile',\n",
       " ':',\n",
       " '+1',\n",
       " '(',\n",
       " '224',\n",
       " ')',\n",
       " '360-4688',\n",
       " '+1',\n",
       " '(',\n",
       " '847',\n",
       " ')',\n",
       " '589-2024',\n",
       " 'Fax',\n",
       " ':',\n",
       " 'Email',\n",
       " ':',\n",
       " 'su.kim',\n",
       " '@',\n",
       " 'abbvie.com',\n",
       " 'EMERGENCY',\n",
       " '24',\n",
       " 'hour',\n",
       " 'Number',\n",
       " ':',\n",
       " '+1',\n",
       " '973-784-6402',\n",
       " '*The',\n",
       " 'specific',\n",
       " 'contact',\n",
       " 'details',\n",
       " 'of',\n",
       " 'the',\n",
       " 'AbbVie',\n",
       " 'legal/regulatory',\n",
       " 'entity',\n",
       " '(',\n",
       " 'person',\n",
       " ')',\n",
       " 'within',\n",
       " 'the',\n",
       " 'relevant',\n",
       " 'country',\n",
       " 'are',\n",
       " 'provided',\n",
       " 'within',\n",
       " 'the',\n",
       " 'clinical',\n",
       " 'trial',\n",
       " 'agreement',\n",
       " 'with',\n",
       " 'the',\n",
       " 'Investigator/Institution',\n",
       " 'and',\n",
       " 'in',\n",
       " 'the',\n",
       " 'Clinical',\n",
       " 'Trial',\n",
       " 'Application',\n",
       " 'with',\n",
       " 'the',\n",
       " 'Competent',\n",
       " 'Authority',\n",
       " '.',\n",
       " 'Additional',\n",
       " 'study',\n",
       " 'contact',\n",
       " 'information',\n",
       " 'can',\n",
       " 'be',\n",
       " 'found',\n",
       " 'in',\n",
       " 'the',\n",
       " 'Operations',\n",
       " 'Manual',\n",
       " '(',\n",
       " 'Appendix',\n",
       " 'F',\n",
       " ')',\n",
       " '.',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'or',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'is',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'from',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " 'Page',\n",
       " '1',\n",
       " 'of',\n",
       " '42',\n",
       " 'TABLE',\n",
       " 'OF',\n",
       " 'CONTENTS',\n",
       " '1',\n",
       " 'SYNOPSIS',\n",
       " '2',\n",
       " '2.1',\n",
       " '2.2',\n",
       " 'INTRODUCTION',\n",
       " 'BACKGROUND',\n",
       " 'AND',\n",
       " 'RATIONALE',\n",
       " 'BENEFITS',\n",
       " 'AND',\n",
       " 'RISKS',\n",
       " 'TO',\n",
       " 'SUBJECTS',\n",
       " 'STUDY',\n",
       " 'OBJECTIVES',\n",
       " 'AND',\n",
       " 'ENDPOINTS',\n",
       " '3',\n",
       " '3.1',\n",
       " 'OBJECTIVES',\n",
       " '3.2',\n",
       " 'EFFICACY',\n",
       " 'ENDPOINTS',\n",
       " 'SAFETY',\n",
       " 'ENDPOINTS',\n",
       " '3.3',\n",
       " 'INVESTIGATIONAL',\n",
       " 'PLAN',\n",
       " '4',\n",
       " '4.1',\n",
       " 'OVERALL',\n",
       " 'STUDY',\n",
       " 'DESIGN',\n",
       " 'AND',\n",
       " 'PLAN',\n",
       " '4.2',\n",
       " 'DISCUSSION',\n",
       " 'OF',\n",
       " 'STUDY',\n",
       " 'DESIGN',\n",
       " '5',\n",
       " '5.1',\n",
       " '5.2',\n",
       " '5.3',\n",
       " 'STUDY',\n",
       " 'ACTIVITIES',\n",
       " 'ELIGIBILITY',\n",
       " 'CRITERIA',\n",
       " 'CONTRACEPTION',\n",
       " 'RECOMMENDATIONS',\n",
       " 'PROHIBITED',\n",
       " 'MEDICATIONS',\n",
       " 'AND',\n",
       " 'THERAPY',\n",
       " 'PRIOR',\n",
       " 'AND',\n",
       " 'CONCOMITANT',\n",
       " 'THERAPY',\n",
       " '5.4',\n",
       " '5.5',\n",
       " 'WITHDRAWAL',\n",
       " 'OF',\n",
       " 'SUBJECTS',\n",
       " 'AND',\n",
       " 'DISCONTINUATION',\n",
       " 'OF',\n",
       " 'STUDY',\n",
       " '5.6',\n",
       " 'FOLLOW-UP',\n",
       " 'FOR',\n",
       " 'SUBJECT',\n",
       " 'WITHDRAWAL',\n",
       " 'FROM',\n",
       " 'STUDY',\n",
       " 'STUDY',\n",
       " 'DRUG',\n",
       " 'RANDOMIZATION/DRUG',\n",
       " 'ASSIGNMENT',\n",
       " 'PROTOCOL',\n",
       " 'DEVIATIONS',\n",
       " 'SAFETY',\n",
       " 'CONSIDERATIONS',\n",
       " 'COMPLAINTS',\n",
       " 'AND',\n",
       " 'ADVERSE',\n",
       " 'EVENTS',\n",
       " 'TOXICITY',\n",
       " 'MANAGEMENT',\n",
       " '5.7',\n",
       " '5.8',\n",
       " '5.9',\n",
       " '6',\n",
       " '6.1',\n",
       " '6.2',\n",
       " 'STATISTICAL',\n",
       " 'METHODS',\n",
       " '&',\n",
       " 'DETERMINATION',\n",
       " 'OF',\n",
       " 'SAMPLE',\n",
       " 'SIZE',\n",
       " '7',\n",
       " '7.1',\n",
       " '7.2',\n",
       " 'DEFINITION',\n",
       " 'FOR',\n",
       " 'ANALYSIS',\n",
       " 'POPULATIONS',\n",
       " 'STATISTICAL',\n",
       " 'AND',\n",
       " 'ANALYTICAL',\n",
       " 'PLANS',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'or',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'is',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'from',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " '4',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '6',\n",
       " '6',\n",
       " '6',\n",
       " '7',\n",
       " '7',\n",
       " '8',\n",
       " '10',\n",
       " '10',\n",
       " '11',\n",
       " '11',\n",
       " '12',\n",
       " '12',\n",
       " '12',\n",
       " '13',\n",
       " '13',\n",
       " '16',\n",
       " '16',\n",
       " '16',\n",
       " '16',\n",
       " 'Page',\n",
       " '2',\n",
       " 'of',\n",
       " '42',\n",
       " '16',\n",
       " '16',\n",
       " '16',\n",
       " '17',\n",
       " '17',\n",
       " '17',\n",
       " '17',\n",
       " '17',\n",
       " '18',\n",
       " '18',\n",
       " '18',\n",
       " '12',\n",
       " '19',\n",
       " '20',\n",
       " '21',\n",
       " '22',\n",
       " '23',\n",
       " '24',\n",
       " '7.3',\n",
       " 'DETERMINATION',\n",
       " 'OF',\n",
       " 'SAMPLE',\n",
       " 'SIZE',\n",
       " '7.4',\n",
       " 'STATISTICAL',\n",
       " 'ANALYSES',\n",
       " 'FOR',\n",
       " 'EFFICACY',\n",
       " 'STATISTICAL',\n",
       " 'ANALYSES',\n",
       " 'FOR',\n",
       " 'SAFETY',\n",
       " '7.5',\n",
       " '8',\n",
       " '8.1',\n",
       " '8.2',\n",
       " '8.3',\n",
       " 'ETHICS',\n",
       " 'INDEPENDENT',\n",
       " 'ETHICS',\n",
       " 'COMMITTEE/INSTITUTIONAL',\n",
       " 'REVIEW',\n",
       " 'BOARD',\n",
       " '(',\n",
       " 'IEC/IRB',\n",
       " ')',\n",
       " 'ETHICAL',\n",
       " 'CONDUCT',\n",
       " 'OF',\n",
       " 'THE',\n",
       " 'STUDY',\n",
       " 'SUBJECT',\n",
       " 'CONFIDENTIALITY',\n",
       " '9',\n",
       " 'SOURCE',\n",
       " 'DOCUMENTS',\n",
       " 'AND',\n",
       " 'CASE',\n",
       " 'REPORT',\n",
       " 'FORM',\n",
       " 'COMPLETION',\n",
       " '10',\n",
       " 'DATA',\n",
       " 'QUALITY',\n",
       " 'ASSURANCE',\n",
       " '11',\n",
       " 'COMPLETION',\n",
       " 'OF',\n",
       " 'THE',\n",
       " 'STUDY',\n",
       " '12',\n",
       " 'REFERENCES',\n",
       " 'LIST',\n",
       " 'OF',\n",
       " 'TABLES',\n",
       " 'TABLE',\n",
       " '1',\n",
       " '.',\n",
       " 'STUDY',\n",
       " 'DRUG',\n",
       " 'INFORMATION',\n",
       " 'LIST',\n",
       " 'OF',\n",
       " 'APPENDICES',\n",
       " 'APPENDIX',\n",
       " 'A',\n",
       " '.',\n",
       " 'STUDY',\n",
       " 'SPECIFIC',\n",
       " 'ABBREVIATIONS',\n",
       " 'AND',\n",
       " 'TERMS',\n",
       " 'APPENDIX',\n",
       " 'B',\n",
       " '.',\n",
       " 'RESPONSIBILITIES',\n",
       " 'OF',\n",
       " 'THE',\n",
       " 'INVESTIGATOR',\n",
       " 'APPENDIX',\n",
       " 'C.',\n",
       " 'LIST',\n",
       " 'OF',\n",
       " 'PROTOCOL',\n",
       " 'SIGNATORIES',\n",
       " 'APPENDIX',\n",
       " 'D.',\n",
       " 'ACTIVITY',\n",
       " 'SCHEDULE',\n",
       " 'APPENDIX',\n",
       " 'E.',\n",
       " 'PROTOCOL',\n",
       " 'SUMMARY',\n",
       " 'OF',\n",
       " 'CHANGES',\n",
       " 'APPENDIX',\n",
       " 'F.',\n",
       " 'OPERATIONS',\n",
       " 'MANUAL',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'or',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'is',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'from',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " 'Page',\n",
       " '3',\n",
       " 'of',\n",
       " '42',\n",
       " 'Title',\n",
       " ':',\n",
       " 'An',\n",
       " 'Extension',\n",
       " 'Study',\n",
       " 'of',\n",
       " 'Venetoclax',\n",
       " 'for',\n",
       " 'Subjects',\n",
       " 'Who',\n",
       " 'Have',\n",
       " 'Completed',\n",
       " 'a',\n",
       " 'Prior',\n",
       " 'Venetoclax',\n",
       " 'Clinical',\n",
       " 'Trial',\n",
       " 'Background',\n",
       " 'and',\n",
       " 'Rationale',\n",
       " ':',\n",
       " '1',\n",
       " 'SYNOPSIS',\n",
       " 'Objective',\n",
       " '(',\n",
       " 's',\n",
       " ')',\n",
       " 'and',\n",
       " 'Endpoint',\n",
       " '(',\n",
       " 's',\n",
       " ')',\n",
       " ':',\n",
       " 'Investigator',\n",
       " '(',\n",
       " 's',\n",
       " ')',\n",
       " ':',\n",
       " 'Study',\n",
       " 'Site',\n",
       " '(',\n",
       " 's',\n",
       " ')',\n",
       " ':',\n",
       " 'Study',\n",
       " 'Population',\n",
       " 'and',\n",
       " 'Number',\n",
       " 'of',\n",
       " 'Subjects',\n",
       " 'to',\n",
       " 'be',\n",
       " 'Enrolled',\n",
       " ':',\n",
       " 'Investigational',\n",
       " 'Plan',\n",
       " ':',\n",
       " 'Key',\n",
       " 'Eligibility',\n",
       " 'Criteria',\n",
       " ':',\n",
       " 'Study',\n",
       " 'Drug',\n",
       " 'and',\n",
       " 'Duration',\n",
       " 'of',\n",
       " 'Treatment',\n",
       " ':',\n",
       " 'Date',\n",
       " 'of',\n",
       " 'Protocol',\n",
       " 'Synopsis',\n",
       " ':',\n",
       " 'The',\n",
       " 'purpose',\n",
       " 'of',\n",
       " 'this',\n",
       " 'extension',\n",
       " 'study',\n",
       " 'is',\n",
       " 'to',\n",
       " 'provide',\n",
       " 'venetoclax',\n",
       " 'and',\n",
       " 'obtain',\n",
       " 'long-term',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'for',\n",
       " 'subjects',\n",
       " 'who',\n",
       " 'continue',\n",
       " 'to',\n",
       " 'tolerate',\n",
       " 'and',\n",
       " 'derive',\n",
       " 'benefit',\n",
       " 'from',\n",
       " 'receiving',\n",
       " 'venetoclax',\n",
       " 'in',\n",
       " 'ongoing',\n",
       " 'studies',\n",
       " '.',\n",
       " 'Objective',\n",
       " ':',\n",
       " 'obtain',\n",
       " 'long-term',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'for',\n",
       " 'subjects',\n",
       " 'rolling',\n",
       " 'over',\n",
       " 'from',\n",
       " 'ongoing',\n",
       " 'venetoclax',\n",
       " 'studies',\n",
       " '.',\n",
       " 'Endpoint',\n",
       " ':',\n",
       " 'adverse',\n",
       " 'event',\n",
       " 'collection',\n",
       " '.',\n",
       " 'There',\n",
       " 'are',\n",
       " 'no',\n",
       " 'formal',\n",
       " 'statistical',\n",
       " 'analyses',\n",
       " 'of',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'for',\n",
       " 'this',\n",
       " 'study',\n",
       " '.',\n",
       " 'Multicenter',\n",
       " 'Approximately',\n",
       " '325',\n",
       " 'sites',\n",
       " '.',\n",
       " 'Approximately',\n",
       " '550',\n",
       " 'subjects',\n",
       " '.',\n",
       " 'This',\n",
       " 'is',\n",
       " 'a',\n",
       " 'Phase',\n",
       " '3',\n",
       " ',',\n",
       " 'open-label',\n",
       " ',',\n",
       " 'multicenter',\n",
       " ',',\n",
       " 'extension',\n",
       " 'study',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'will',\n",
       " 'receive',\n",
       " 'venetoclax',\n",
       " 'daily',\n",
       " 'until',\n",
       " 'discontinuing',\n",
       " 'from',\n",
       " 'the',\n",
       " 'study',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'who',\n",
       " 'are',\n",
       " 'receiving',\n",
       " 'other',\n",
       " 'study',\n",
       " 'agents',\n",
       " 'at',\n",
       " 'the',\n",
       " 'time',\n",
       " 'of',\n",
       " 'study',\n",
       " 'entry',\n",
       " 'may',\n",
       " 'continue',\n",
       " 'to',\n",
       " 'receive',\n",
       " 'them',\n",
       " ',',\n",
       " 'but',\n",
       " 'these',\n",
       " 'agents',\n",
       " 'will',\n",
       " 'not',\n",
       " 'be',\n",
       " 'supplied',\n",
       " 'by',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'will',\n",
       " 'be',\n",
       " 'evaluated',\n",
       " 'per',\n",
       " 'the',\n",
       " 'standard',\n",
       " 'of',\n",
       " 'care',\n",
       " 'and',\n",
       " 'will',\n",
       " 'return',\n",
       " 'every',\n",
       " '12',\n",
       " 'weeks',\n",
       " '(',\n",
       " '±',\n",
       " '2',\n",
       " 'weeks',\n",
       " ')',\n",
       " 'to',\n",
       " 'continue',\n",
       " 'dispensation',\n",
       " 'of',\n",
       " 'venetoclax',\n",
       " 'and',\n",
       " 'evaluation',\n",
       " 'of',\n",
       " 'adverse',\n",
       " 'events',\n",
       " ',',\n",
       " 'serious',\n",
       " 'adverse',\n",
       " 'events',\n",
       " ',',\n",
       " 'and',\n",
       " 'use',\n",
       " 'of',\n",
       " 'concomitant',\n",
       " 'medications',\n",
       " '.',\n",
       " 'Subject',\n",
       " 'has',\n",
       " 'been',\n",
       " 'enrolled',\n",
       " 'and',\n",
       " 'dosed',\n",
       " 'in',\n",
       " 'an',\n",
       " 'ongoing',\n",
       " 'venetoclax',\n",
       " 'study',\n",
       " 'and',\n",
       " 'continues',\n",
       " 'to',\n",
       " 'tolerate',\n",
       " 'and',\n",
       " 'derive',\n",
       " 'benefit',\n",
       " 'from',\n",
       " 'the',\n",
       " 'study',\n",
       " 'drug',\n",
       " '.',\n",
       " 'Male',\n",
       " 'subjects',\n",
       " 'must',\n",
       " 'agree',\n",
       " 'to',\n",
       " 'refrain',\n",
       " 'from',\n",
       " 'sperm',\n",
       " 'donation',\n",
       " '.',\n",
       " 'Female',\n",
       " 'subjects',\n",
       " 'must',\n",
       " 'not',\n",
       " 'be',\n",
       " 'pregnant',\n",
       " 'or',\n",
       " 'breastfeeding',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'will',\n",
       " 'continue',\n",
       " 'to',\n",
       " 'receive',\n",
       " 'venetoclax',\n",
       " 'orally',\n",
       " ',',\n",
       " 'once',\n",
       " 'daily',\n",
       " ',',\n",
       " 'continuously',\n",
       " 'at',\n",
       " 'the',\n",
       " 'same',\n",
       " 'dosage',\n",
       " 'strength',\n",
       " 'administered',\n",
       " 'to',\n",
       " 'them',\n",
       " 'during',\n",
       " 'the',\n",
       " 'previous',\n",
       " 'study',\n",
       " 'in',\n",
       " 'which',\n",
       " 'they',\n",
       " 'were',\n",
       " 'enrolled',\n",
       " '.',\n",
       " 'Venetoclax',\n",
       " '(',\n",
       " 'ABT-199',\n",
       " ')',\n",
       " 'will',\n",
       " 'be',\n",
       " 'supplied',\n",
       " 'as',\n",
       " 'film-coated',\n",
       " 'tables',\n",
       " 'of',\n",
       " '50',\n",
       " 'mg',\n",
       " 'or',\n",
       " '100',\n",
       " 'mg',\n",
       " 'dosage',\n",
       " 'strengths',\n",
       " '.',\n",
       " 'Venetoclax',\n",
       " 'will',\n",
       " 'also',\n",
       " 'be',\n",
       " 'supplied',\n",
       " 'as',\n",
       " 'tablets',\n",
       " 'for',\n",
       " 'oral',\n",
       " 'suspension',\n",
       " 'at',\n",
       " '2.5',\n",
       " 'mg',\n",
       " ',',\n",
       " '10',\n",
       " 'mg',\n",
       " ',',\n",
       " 'or',\n",
       " '25',\n",
       " 'mg',\n",
       " 'dosage',\n",
       " 'strengths',\n",
       " '.',\n",
       " 'Once',\n",
       " 'venetoclax',\n",
       " 'is',\n",
       " 'approved',\n",
       " 'and',\n",
       " 'commercially',\n",
       " 'available',\n",
       " 'in',\n",
       " 'the',\n",
       " 'country',\n",
       " 'of',\n",
       " 'participation',\n",
       " ',',\n",
       " 'AbbVie',\n",
       " 'will',\n",
       " 'not',\n",
       " 'provide',\n",
       " 'venetoclax',\n",
       " 'or',\n",
       " 'any',\n",
       " 'other',\n",
       " 'therapy',\n",
       " 'once',\n",
       " 'the',\n",
       " 'subject',\n",
       " \"'s\",\n",
       " 'participation',\n",
       " 'is',\n",
       " 'concluded',\n",
       " '.',\n",
       " '15',\n",
       " 'March',\n",
       " '2019',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'or',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'is',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'from',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " 'Page',\n",
       " '4',\n",
       " 'of',\n",
       " '42',\n",
       " '2',\n",
       " 'INTRODUCTION',\n",
       " '2.1',\n",
       " 'Background',\n",
       " 'and',\n",
       " ...]"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokens = word_tokenize(output)\n",
    "tokens"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "len(tokens)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Protocol',\n",
       " 'Study',\n",
       " 'M19-388',\n",
       " 'Venetoclax',\n",
       " 'Extension',\n",
       " 'Study',\n",
       " '2.0',\n",
       " 'AbbVie',\n",
       " 'VERSION',\n",
       " 'SPONSOR',\n",
       " 'ABBVIE',\n",
       " 'INVESTIGATIONAL',\n",
       " 'PRODUCT',\n",
       " 'DATE',\n",
       " '15',\n",
       " 'March',\n",
       " '2019',\n",
       " 'Venetoclax',\n",
       " 'ABT-199',\n",
       " 'EUDRACT',\n",
       " 'NUMBER',\n",
       " 'OF',\n",
       " 'SITES',\n",
       " 'Approximately',\n",
       " '325',\n",
       " 'sites',\n",
       " '35',\n",
       " 'countries',\n",
       " '2018-004356-38',\n",
       " 'FULL',\n",
       " 'TITLE',\n",
       " 'An',\n",
       " 'Extension',\n",
       " 'Study',\n",
       " 'Venetoclax',\n",
       " 'Subjects',\n",
       " 'Who',\n",
       " 'Have',\n",
       " 'Completed',\n",
       " 'Prior',\n",
       " 'Venetoclax',\n",
       " 'Clinical',\n",
       " 'Trial',\n",
       " 'PRINCIPAL',\n",
       " 'INVESTIGATOR',\n",
       " 'S',\n",
       " 'Investigator',\n",
       " 'information',\n",
       " 'file',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'SPONSOR/EMERGENCY',\n",
       " 'MEDICAL',\n",
       " 'CONTACT',\n",
       " '*',\n",
       " 'Su',\n",
       " 'Young',\n",
       " 'Kim',\n",
       " 'MD',\n",
       " 'PhD',\n",
       " 'AbbVie',\n",
       " 'Dept',\n",
       " '.',\n",
       " 'R48K',\n",
       " 'Bldg',\n",
       " '.',\n",
       " 'AP30-3',\n",
       " '1',\n",
       " 'North',\n",
       " 'Waukegan',\n",
       " 'Road',\n",
       " 'North',\n",
       " 'Chicago',\n",
       " 'IL',\n",
       " '60064',\n",
       " 'Office',\n",
       " '+1',\n",
       " '847',\n",
       " '937-4903',\n",
       " 'Mobile',\n",
       " '+1',\n",
       " '224',\n",
       " '360-4688',\n",
       " '+1',\n",
       " '847',\n",
       " '589-2024',\n",
       " 'Fax',\n",
       " 'Email',\n",
       " 'su.kim',\n",
       " '@',\n",
       " 'abbvie.com',\n",
       " 'EMERGENCY',\n",
       " '24',\n",
       " 'hour',\n",
       " 'Number',\n",
       " '+1',\n",
       " '973-784-6402',\n",
       " '*The',\n",
       " 'specific',\n",
       " 'contact',\n",
       " 'details',\n",
       " 'AbbVie',\n",
       " 'legal/regulatory',\n",
       " 'entity',\n",
       " 'person',\n",
       " 'within',\n",
       " 'relevant',\n",
       " 'country',\n",
       " 'provided',\n",
       " 'within',\n",
       " 'clinical',\n",
       " 'trial',\n",
       " 'agreement',\n",
       " 'Investigator/Institution',\n",
       " 'Clinical',\n",
       " 'Trial',\n",
       " 'Application',\n",
       " 'Competent',\n",
       " 'Authority',\n",
       " '.',\n",
       " 'Additional',\n",
       " 'study',\n",
       " 'contact',\n",
       " 'information',\n",
       " 'found',\n",
       " 'Operations',\n",
       " 'Manual',\n",
       " 'Appendix',\n",
       " 'F',\n",
       " '.',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " 'Page',\n",
       " '1',\n",
       " '42',\n",
       " 'TABLE',\n",
       " 'OF',\n",
       " 'CONTENTS',\n",
       " '1',\n",
       " 'SYNOPSIS',\n",
       " '2',\n",
       " '2.1',\n",
       " '2.2',\n",
       " 'INTRODUCTION',\n",
       " 'BACKGROUND',\n",
       " 'AND',\n",
       " 'RATIONALE',\n",
       " 'BENEFITS',\n",
       " 'AND',\n",
       " 'RISKS',\n",
       " 'TO',\n",
       " 'SUBJECTS',\n",
       " 'STUDY',\n",
       " 'OBJECTIVES',\n",
       " 'AND',\n",
       " 'ENDPOINTS',\n",
       " '3',\n",
       " '3.1',\n",
       " 'OBJECTIVES',\n",
       " '3.2',\n",
       " 'EFFICACY',\n",
       " 'ENDPOINTS',\n",
       " 'SAFETY',\n",
       " 'ENDPOINTS',\n",
       " '3.3',\n",
       " 'INVESTIGATIONAL',\n",
       " 'PLAN',\n",
       " '4',\n",
       " '4.1',\n",
       " 'OVERALL',\n",
       " 'STUDY',\n",
       " 'DESIGN',\n",
       " 'AND',\n",
       " 'PLAN',\n",
       " '4.2',\n",
       " 'DISCUSSION',\n",
       " 'OF',\n",
       " 'STUDY',\n",
       " 'DESIGN',\n",
       " '5',\n",
       " '5.1',\n",
       " '5.2',\n",
       " '5.3',\n",
       " 'STUDY',\n",
       " 'ACTIVITIES',\n",
       " 'ELIGIBILITY',\n",
       " 'CRITERIA',\n",
       " 'CONTRACEPTION',\n",
       " 'RECOMMENDATIONS',\n",
       " 'PROHIBITED',\n",
       " 'MEDICATIONS',\n",
       " 'AND',\n",
       " 'THERAPY',\n",
       " 'PRIOR',\n",
       " 'AND',\n",
       " 'CONCOMITANT',\n",
       " 'THERAPY',\n",
       " '5.4',\n",
       " '5.5',\n",
       " 'WITHDRAWAL',\n",
       " 'OF',\n",
       " 'SUBJECTS',\n",
       " 'AND',\n",
       " 'DISCONTINUATION',\n",
       " 'OF',\n",
       " 'STUDY',\n",
       " '5.6',\n",
       " 'FOLLOW-UP',\n",
       " 'FOR',\n",
       " 'SUBJECT',\n",
       " 'WITHDRAWAL',\n",
       " 'FROM',\n",
       " 'STUDY',\n",
       " 'STUDY',\n",
       " 'DRUG',\n",
       " 'RANDOMIZATION/DRUG',\n",
       " 'ASSIGNMENT',\n",
       " 'PROTOCOL',\n",
       " 'DEVIATIONS',\n",
       " 'SAFETY',\n",
       " 'CONSIDERATIONS',\n",
       " 'COMPLAINTS',\n",
       " 'AND',\n",
       " 'ADVERSE',\n",
       " 'EVENTS',\n",
       " 'TOXICITY',\n",
       " 'MANAGEMENT',\n",
       " '5.7',\n",
       " '5.8',\n",
       " '5.9',\n",
       " '6',\n",
       " '6.1',\n",
       " '6.2',\n",
       " 'STATISTICAL',\n",
       " 'METHODS',\n",
       " '&',\n",
       " 'DETERMINATION',\n",
       " 'OF',\n",
       " 'SAMPLE',\n",
       " 'SIZE',\n",
       " '7',\n",
       " '7.1',\n",
       " '7.2',\n",
       " 'DEFINITION',\n",
       " 'FOR',\n",
       " 'ANALYSIS',\n",
       " 'POPULATIONS',\n",
       " 'STATISTICAL',\n",
       " 'AND',\n",
       " 'ANALYTICAL',\n",
       " 'PLANS',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " '4',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '5',\n",
       " '6',\n",
       " '6',\n",
       " '6',\n",
       " '7',\n",
       " '7',\n",
       " '8',\n",
       " '10',\n",
       " '10',\n",
       " '11',\n",
       " '11',\n",
       " '12',\n",
       " '12',\n",
       " '12',\n",
       " '13',\n",
       " '13',\n",
       " '16',\n",
       " '16',\n",
       " '16',\n",
       " '16',\n",
       " 'Page',\n",
       " '2',\n",
       " '42',\n",
       " '16',\n",
       " '16',\n",
       " '16',\n",
       " '17',\n",
       " '17',\n",
       " '17',\n",
       " '17',\n",
       " '17',\n",
       " '18',\n",
       " '18',\n",
       " '18',\n",
       " '12',\n",
       " '19',\n",
       " '20',\n",
       " '21',\n",
       " '22',\n",
       " '23',\n",
       " '24',\n",
       " '7.3',\n",
       " 'DETERMINATION',\n",
       " 'OF',\n",
       " 'SAMPLE',\n",
       " 'SIZE',\n",
       " '7.4',\n",
       " 'STATISTICAL',\n",
       " 'ANALYSES',\n",
       " 'FOR',\n",
       " 'EFFICACY',\n",
       " 'STATISTICAL',\n",
       " 'ANALYSES',\n",
       " 'FOR',\n",
       " 'SAFETY',\n",
       " '7.5',\n",
       " '8',\n",
       " '8.1',\n",
       " '8.2',\n",
       " '8.3',\n",
       " 'ETHICS',\n",
       " 'INDEPENDENT',\n",
       " 'ETHICS',\n",
       " 'COMMITTEE/INSTITUTIONAL',\n",
       " 'REVIEW',\n",
       " 'BOARD',\n",
       " 'IEC/IRB',\n",
       " 'ETHICAL',\n",
       " 'CONDUCT',\n",
       " 'OF',\n",
       " 'THE',\n",
       " 'STUDY',\n",
       " 'SUBJECT',\n",
       " 'CONFIDENTIALITY',\n",
       " '9',\n",
       " 'SOURCE',\n",
       " 'DOCUMENTS',\n",
       " 'AND',\n",
       " 'CASE',\n",
       " 'REPORT',\n",
       " 'FORM',\n",
       " 'COMPLETION',\n",
       " '10',\n",
       " 'DATA',\n",
       " 'QUALITY',\n",
       " 'ASSURANCE',\n",
       " '11',\n",
       " 'COMPLETION',\n",
       " 'OF',\n",
       " 'THE',\n",
       " 'STUDY',\n",
       " '12',\n",
       " 'REFERENCES',\n",
       " 'LIST',\n",
       " 'OF',\n",
       " 'TABLES',\n",
       " 'TABLE',\n",
       " '1',\n",
       " '.',\n",
       " 'STUDY',\n",
       " 'DRUG',\n",
       " 'INFORMATION',\n",
       " 'LIST',\n",
       " 'OF',\n",
       " 'APPENDICES',\n",
       " 'APPENDIX',\n",
       " 'A',\n",
       " '.',\n",
       " 'STUDY',\n",
       " 'SPECIFIC',\n",
       " 'ABBREVIATIONS',\n",
       " 'AND',\n",
       " 'TERMS',\n",
       " 'APPENDIX',\n",
       " 'B',\n",
       " '.',\n",
       " 'RESPONSIBILITIES',\n",
       " 'OF',\n",
       " 'THE',\n",
       " 'INVESTIGATOR',\n",
       " 'APPENDIX',\n",
       " 'C.',\n",
       " 'LIST',\n",
       " 'OF',\n",
       " 'PROTOCOL',\n",
       " 'SIGNATORIES',\n",
       " 'APPENDIX',\n",
       " 'D.',\n",
       " 'ACTIVITY',\n",
       " 'SCHEDULE',\n",
       " 'APPENDIX',\n",
       " 'E.',\n",
       " 'PROTOCOL',\n",
       " 'SUMMARY',\n",
       " 'OF',\n",
       " 'CHANGES',\n",
       " 'APPENDIX',\n",
       " 'F.',\n",
       " 'OPERATIONS',\n",
       " 'MANUAL',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " 'Page',\n",
       " '3',\n",
       " '42',\n",
       " 'Title',\n",
       " 'An',\n",
       " 'Extension',\n",
       " 'Study',\n",
       " 'Venetoclax',\n",
       " 'Subjects',\n",
       " 'Who',\n",
       " 'Have',\n",
       " 'Completed',\n",
       " 'Prior',\n",
       " 'Venetoclax',\n",
       " 'Clinical',\n",
       " 'Trial',\n",
       " 'Background',\n",
       " 'Rationale',\n",
       " '1',\n",
       " 'SYNOPSIS',\n",
       " 'Objective',\n",
       " 'Endpoint',\n",
       " 'Investigator',\n",
       " 'Study',\n",
       " 'Site',\n",
       " 'Study',\n",
       " 'Population',\n",
       " 'Number',\n",
       " 'Subjects',\n",
       " 'Enrolled',\n",
       " 'Investigational',\n",
       " 'Plan',\n",
       " 'Key',\n",
       " 'Eligibility',\n",
       " 'Criteria',\n",
       " 'Study',\n",
       " 'Drug',\n",
       " 'Duration',\n",
       " 'Treatment',\n",
       " 'Date',\n",
       " 'Protocol',\n",
       " 'Synopsis',\n",
       " 'The',\n",
       " 'purpose',\n",
       " 'extension',\n",
       " 'study',\n",
       " 'provide',\n",
       " 'venetoclax',\n",
       " 'obtain',\n",
       " 'long-term',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'subjects',\n",
       " 'continue',\n",
       " 'tolerate',\n",
       " 'derive',\n",
       " 'benefit',\n",
       " 'receiving',\n",
       " 'venetoclax',\n",
       " 'ongoing',\n",
       " 'studies',\n",
       " '.',\n",
       " 'Objective',\n",
       " 'obtain',\n",
       " 'long-term',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'subjects',\n",
       " 'rolling',\n",
       " 'ongoing',\n",
       " 'venetoclax',\n",
       " 'studies',\n",
       " '.',\n",
       " 'Endpoint',\n",
       " 'adverse',\n",
       " 'event',\n",
       " 'collection',\n",
       " '.',\n",
       " 'There',\n",
       " 'formal',\n",
       " 'statistical',\n",
       " 'analyses',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'study',\n",
       " '.',\n",
       " 'Multicenter',\n",
       " 'Approximately',\n",
       " '325',\n",
       " 'sites',\n",
       " '.',\n",
       " 'Approximately',\n",
       " '550',\n",
       " 'subjects',\n",
       " '.',\n",
       " 'This',\n",
       " 'Phase',\n",
       " '3',\n",
       " 'open-label',\n",
       " 'multicenter',\n",
       " 'extension',\n",
       " 'study',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'receive',\n",
       " 'venetoclax',\n",
       " 'daily',\n",
       " 'discontinuing',\n",
       " 'study',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'receiving',\n",
       " 'study',\n",
       " 'agents',\n",
       " 'time',\n",
       " 'study',\n",
       " 'entry',\n",
       " 'may',\n",
       " 'continue',\n",
       " 'receive',\n",
       " 'agents',\n",
       " 'supplied',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'evaluated',\n",
       " 'per',\n",
       " 'standard',\n",
       " 'care',\n",
       " 'return',\n",
       " 'every',\n",
       " '12',\n",
       " 'weeks',\n",
       " '±',\n",
       " '2',\n",
       " 'weeks',\n",
       " 'continue',\n",
       " 'dispensation',\n",
       " 'venetoclax',\n",
       " 'evaluation',\n",
       " 'adverse',\n",
       " 'events',\n",
       " 'serious',\n",
       " 'adverse',\n",
       " 'events',\n",
       " 'use',\n",
       " 'concomitant',\n",
       " 'medications',\n",
       " '.',\n",
       " 'Subject',\n",
       " 'enrolled',\n",
       " 'dosed',\n",
       " 'ongoing',\n",
       " 'venetoclax',\n",
       " 'study',\n",
       " 'continues',\n",
       " 'tolerate',\n",
       " 'derive',\n",
       " 'benefit',\n",
       " 'study',\n",
       " 'drug',\n",
       " '.',\n",
       " 'Male',\n",
       " 'subjects',\n",
       " 'must',\n",
       " 'agree',\n",
       " 'refrain',\n",
       " 'sperm',\n",
       " 'donation',\n",
       " '.',\n",
       " 'Female',\n",
       " 'subjects',\n",
       " 'must',\n",
       " 'pregnant',\n",
       " 'breastfeeding',\n",
       " '.',\n",
       " 'Subjects',\n",
       " 'continue',\n",
       " 'receive',\n",
       " 'venetoclax',\n",
       " 'orally',\n",
       " 'daily',\n",
       " 'continuously',\n",
       " 'dosage',\n",
       " 'strength',\n",
       " 'administered',\n",
       " 'previous',\n",
       " 'study',\n",
       " 'enrolled',\n",
       " '.',\n",
       " 'Venetoclax',\n",
       " 'ABT-199',\n",
       " 'supplied',\n",
       " 'film-coated',\n",
       " 'tables',\n",
       " '50',\n",
       " 'mg',\n",
       " '100',\n",
       " 'mg',\n",
       " 'dosage',\n",
       " 'strengths',\n",
       " '.',\n",
       " 'Venetoclax',\n",
       " 'also',\n",
       " 'supplied',\n",
       " 'tablets',\n",
       " 'oral',\n",
       " 'suspension',\n",
       " '2.5',\n",
       " 'mg',\n",
       " '10',\n",
       " 'mg',\n",
       " '25',\n",
       " 'mg',\n",
       " 'dosage',\n",
       " 'strengths',\n",
       " '.',\n",
       " 'Once',\n",
       " 'venetoclax',\n",
       " 'approved',\n",
       " 'commercially',\n",
       " 'available',\n",
       " 'country',\n",
       " 'participation',\n",
       " 'AbbVie',\n",
       " 'provide',\n",
       " 'venetoclax',\n",
       " 'therapy',\n",
       " 'subject',\n",
       " \"'s\",\n",
       " 'participation',\n",
       " 'concluded',\n",
       " '.',\n",
       " '15',\n",
       " 'March',\n",
       " '2019',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " 'Mar',\n",
       " '2019',\n",
       " '-',\n",
       " 'Final',\n",
       " 'Copy',\n",
       " 'Page',\n",
       " '4',\n",
       " '42',\n",
       " '2',\n",
       " 'INTRODUCTION',\n",
       " '2.1',\n",
       " 'Background',\n",
       " 'Rationale',\n",
       " 'Why',\n",
       " 'Is',\n",
       " 'This',\n",
       " 'Study',\n",
       " 'Being',\n",
       " 'Conducted',\n",
       " 'AbbVie',\n",
       " 'developing',\n",
       " 'potent',\n",
       " 'selective',\n",
       " 'orally',\n",
       " 'bioavailable',\n",
       " 'small',\n",
       " 'molecule',\n",
       " 'inhibitor',\n",
       " 'B-cell',\n",
       " 'lymphoma',\n",
       " 'BCL',\n",
       " '-2',\n",
       " 'venetoclax',\n",
       " 'also',\n",
       " 'referred',\n",
       " 'ABT-199',\n",
       " 'A-1195425.0',\n",
       " 'GDC-0199',\n",
       " 'RO5537382',\n",
       " 'Venclexta®',\n",
       " 'Venclyxto®',\n",
       " 'may',\n",
       " 'address',\n",
       " 'current',\n",
       " 'treatment',\n",
       " 'needs',\n",
       " 'patients',\n",
       " 'chronic',\n",
       " 'lymphocytic',\n",
       " 'leukemia',\n",
       " 'CLL',\n",
       " 'acute',\n",
       " 'myeloid',\n",
       " 'leukemia',\n",
       " 'AML',\n",
       " 'multiple',\n",
       " 'myeloma',\n",
       " 'MM',\n",
       " 'Non-Hodgkin',\n",
       " \"'s\",\n",
       " 'lymphoma',\n",
       " 'NHL',\n",
       " 'acute',\n",
       " 'lymphoblastic',\n",
       " 'leukemia',\n",
       " 'ALL',\n",
       " '.',\n",
       " 'Additional',\n",
       " 'details',\n",
       " 'found',\n",
       " 'Venetoclax',\n",
       " 'Investigator',\n",
       " \"'s\",\n",
       " 'Brochure.1',\n",
       " 'The',\n",
       " 'purpose',\n",
       " 'extension',\n",
       " 'study',\n",
       " 'provide',\n",
       " 'venetoclax',\n",
       " 'obtain',\n",
       " 'long-term',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'subjects',\n",
       " 'continue',\n",
       " 'tolerate',\n",
       " 'derive',\n",
       " 'benefit',\n",
       " 'receiving',\n",
       " 'venetoclax',\n",
       " 'ongoing',\n",
       " 'studies',\n",
       " '.',\n",
       " 'Clinical',\n",
       " 'Hypothesis',\n",
       " 'No',\n",
       " 'clinical',\n",
       " 'hypotheses',\n",
       " 'tested',\n",
       " '.',\n",
       " '2.2',\n",
       " 'Benefits',\n",
       " 'Risks',\n",
       " 'Subjects',\n",
       " 'As',\n",
       " '28',\n",
       " 'November',\n",
       " '2017',\n",
       " 'total',\n",
       " '2,495',\n",
       " 'subjects',\n",
       " 'received',\n",
       " 'treatment',\n",
       " 'venetoclax',\n",
       " 'across',\n",
       " 'company-sponsored',\n",
       " 'clinical',\n",
       " 'studies',\n",
       " '.',\n",
       " 'Efficacy',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'completed',\n",
       " 'ongoing',\n",
       " 'studies',\n",
       " 'support',\n",
       " 'development',\n",
       " 'venetoclax',\n",
       " 'subjects',\n",
       " 'CLL',\n",
       " 'AML',\n",
       " 'MM',\n",
       " 'NHL',\n",
       " 'ALL',\n",
       " '.',\n",
       " 'For',\n",
       " 'details',\n",
       " 'refer',\n",
       " 'Venetoclax',\n",
       " 'Investigator',\n",
       " \"'s\",\n",
       " 'Brochure.1',\n",
       " '3',\n",
       " 'STUDY',\n",
       " 'OBJECTIVES',\n",
       " 'AND',\n",
       " 'ENDPOINTS',\n",
       " '3.1',\n",
       " 'Objectives',\n",
       " 'The',\n",
       " 'primary',\n",
       " 'objective',\n",
       " 'obtain',\n",
       " 'long-term',\n",
       " 'safety',\n",
       " 'data',\n",
       " 'subjects',\n",
       " 'ongoing',\n",
       " 'venetoclax',\n",
       " 'studies',\n",
       " '.',\n",
       " '3.2',\n",
       " 'Efficacy',\n",
       " 'Endpoints',\n",
       " 'There',\n",
       " 'efficacy',\n",
       " 'objectives',\n",
       " 'endpoints',\n",
       " 'extension',\n",
       " 'study',\n",
       " '.',\n",
       " '3.3',\n",
       " 'Safety',\n",
       " 'Endpoints',\n",
       " 'Safety',\n",
       " 'evaluations',\n",
       " 'include',\n",
       " 'adverse',\n",
       " 'event',\n",
       " 'monitoring',\n",
       " 'measure',\n",
       " 'safety',\n",
       " 'tolerability',\n",
       " 'entire',\n",
       " 'study',\n",
       " 'duration',\n",
       " '.',\n",
       " 'All',\n",
       " 'deaths',\n",
       " 'study',\n",
       " 'also',\n",
       " 'collected',\n",
       " '.',\n",
       " 'Adverse',\n",
       " 'events',\n",
       " 'collected',\n",
       " 'time',\n",
       " 'enrollment',\n",
       " 'end',\n",
       " 'study',\n",
       " '.',\n",
       " 'All',\n",
       " 'adverse',\n",
       " 'events',\n",
       " 'regardless',\n",
       " 'seriousness',\n",
       " 'causality',\n",
       " 'reported',\n",
       " 'Follow-up',\n",
       " 'Period',\n",
       " '.',\n",
       " 'Details',\n",
       " 'STUDY',\n",
       " 'M19-388',\n",
       " '|',\n",
       " 'Version',\n",
       " '2.0',\n",
       " '/',\n",
       " 'EudraCT',\n",
       " '2018-004356-38',\n",
       " 'CONFIDENTIAL',\n",
       " 'INFORMATION',\n",
       " 'No',\n",
       " 'use',\n",
       " 'disclosure',\n",
       " 'outside',\n",
       " 'AbbVie',\n",
       " 'permitted',\n",
       " 'without',\n",
       " 'prior',\n",
       " 'written',\n",
       " 'authorization',\n",
       " 'AbbVie',\n",
       " '.',\n",
       " 'VV-TMF-3347647',\n",
       " 'M19-388',\n",
       " 'Protocol',\n",
       " 'Amendment',\n",
       " '-',\n",
       " '15',\n",
       " ...]"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "punctuations = ['(',')',';',':','[',']',',']\n",
    "stop_words = stopwords.words('english')\n",
    "\n",
    "keywords = [word for word in tokens if not word in stop_words and not word in punctuations]\n",
    "\n",
    "keywords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
